Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
| DrugCom Name |
DrugCom ID |
Component Drug |
Indication |
REF |
|
16,16-dimethyl-PGE2 + Ruxolitinib
|
DCU9S4O
|
16,16-dimethyl-PGE2
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
18beta-Glycyrrhetic acid + Ruxolitinib
|
DC6B2YP
|
18beta-Glycyrrhetic acid
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
3-aminobenzamide + Ruxolitinib
|
DCGMKEK
|
3-aminobenzamide
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
6-bromoindirubin-3-oxime + Ruxolitinib
|
DCK4B6R
|
6-bromoindirubin-3-oxime
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
ABIRATERONE + Ruxolitinib
|
DCDQQQK
|
ABIRATERONE
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[8] |
|
ABIRATERONE + Ruxolitinib
|
DCAST26
|
ABIRATERONE
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
ABIRATERONE + Ruxolitinib
|
DCCLGM8
|
ABIRATERONE
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[7] |
|
ABIRATERONE + Ruxolitinib
|
DCU94JH
|
ABIRATERONE
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[7] |
|
ABIRATERONE + Ruxolitinib
|
DCSFQ09
|
ABIRATERONE
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
ABIRATERONE + Ruxolitinib
|
DCOSCRC
|
ABIRATERONE
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[7] |
|
ABT-199 + Ruxolitinib
|
DCYM8AB
|
ABT-199
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
ABT-263 + Ruxolitinib
|
DCMAEI8
|
ABT-263
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
ABT-263 + Ruxolitinib
|
DC0CECS
|
ABT-263
|
Hodgkin lymphoma (Cell Line: HDLM-2)
|
[7] |
|
ABT-263 + Ruxolitinib
|
DCRNL13
|
ABT-263
|
Hodgkin lymphoma (Cell Line: L-428)
|
[7] |
|
ABT-737 + Ruxolitinib
|
DC1TDPF
|
ABT-737
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
ABT-751 + Ruxolitinib
|
DCXZZRN
|
ABT-751
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
ABT-888 + Ruxolitinib
|
DC0HPCH
|
ABT-888
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Acipimox + Ruxolitinib
|
DCK1Z6Q
|
Acipimox
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
AEZS-126 + Ruxolitinib
|
DCR4YZT
|
AEZS-126
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Afatinib + Ruxolitinib
|
DC3IXTR
|
Afatinib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
AG-041R + Ruxolitinib
|
DCF0ZCD
|
AG-041R
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
AHPN + Ruxolitinib
|
DCNG89M
|
AHPN
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Alpelisib + Ruxolitinib
|
DC2GFDW
|
Alpelisib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Alvespimycin hydrochloride + Ruxolitinib
|
DCP742A
|
Alvespimycin hydrochloride
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
AMG 900 + Ruxolitinib
|
DCJDH82
|
AMG 900
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Amodiaquine + Ruxolitinib
|
DCOZFS1
|
Amodiaquine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Amonafide + Ruxolitinib
|
DCUTW0G
|
Amonafide
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Anastrozole + Ruxolitinib
|
DCCPFYB
|
Anastrozole
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Apilimod + Ruxolitinib
|
DCFGSXH
|
Apilimod
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[8] |
|
Apilimod + Ruxolitinib
|
DCVBB7T
|
Apilimod
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Apilimod + Ruxolitinib
|
DCPVNYK
|
Apilimod
|
Hodgkin lymphoma (Cell Line: HDLM-2)
|
[7] |
|
Apilimod + Ruxolitinib
|
DCCBLQ4
|
Apilimod
|
Hodgkin lymphoma (Cell Line: U-HO1)
|
[7] |
|
AR-42 + Ruxolitinib
|
DC44XMO
|
AR-42
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Arbidol + Ruxolitinib
|
DCHHGOI
|
Arbidol
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Arfolitixorin + Ruxolitinib
|
DCIW70F
|
Arfolitixorin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
ARRY-520 + Ruxolitinib
|
DCLBFSC
|
ARRY-520
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
AS-15 + Ruxolitinib
|
DCV3S4C
|
AS-15
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
AS602868 + Ruxolitinib
|
DCCC0N9
|
AS602868
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
AS602868 + Ruxolitinib
|
DCK7JSQ
|
AS602868
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Auranofin + Ruxolitinib
|
DCMO455
|
Auranofin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
AXL-1717 + Ruxolitinib
|
DC5DW0G
|
AXL-1717
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Azacitidine + Ruxolitinib
|
DCO99M8
|
Azacitidine
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Azathioprine + Ruxolitinib
|
DCTWW3J
|
Azathioprine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
AZD-1152-HQPA + Ruxolitinib
|
DC79XXH
|
AZD-1152-HQPA
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Azd2014 + Ruxolitinib
|
DCMI35H
|
Azd2014
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
AZD5363 + Ruxolitinib
|
DCXKTS5
|
AZD5363
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
AZD6482 + Ruxolitinib
|
DCZ3BKT
|
AZD6482
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
AZD7762 + Ruxolitinib
|
DCNLIKY
|
AZD7762
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
AZD8055 + Ruxolitinib
|
DCHLSIF
|
AZD8055
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
AZD8055 + Ruxolitinib
|
DCL1DI2
|
AZD8055
|
Hodgkin lymphoma (Cell Line: HDLM-2)
|
[8] |
|
AZD8055 + Ruxolitinib
|
DCU160P
|
AZD8055
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
AZD9668 + Ruxolitinib
|
DCUWUGT
|
AZD9668
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Bafilomycin A1 + Ruxolitinib
|
DC9OA86
|
Bafilomycin A1
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
BAG956 + Ruxolitinib
|
DCRNGDH
|
BAG956
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
BAG956 + Ruxolitinib
|
DCL3RAK
|
BAG956
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Bardoxolone methyl + Ruxolitinib
|
DC3XQPZ
|
Bardoxolone methyl
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Belinostat + Ruxolitinib
|
DCIKV4T
|
Belinostat
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Bendamustine hydrochloride + Ruxolitinib
|
DCHA24S
|
Bendamustine hydrochloride
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Betamethasone valerate + Ruxolitinib
|
DC5B21I
|
Betamethasone valerate
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
BGT226 + Ruxolitinib
|
DCD51PE
|
BGT226
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
BI 2536 + Ruxolitinib
|
DC724R9
|
BI 2536
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
BIO-300 + Ruxolitinib
|
DCNZHJN
|
BIO-300
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Biperiden + Ruxolitinib
|
DC0Z7YG
|
Biperiden
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Birinapant + Ruxolitinib
|
DC6V792
|
Birinapant
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
BIX-01294 + Ruxolitinib
|
DCVIHG2
|
BIX-01294
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
BIX-01294 + Ruxolitinib
|
DCECH1I
|
BIX-01294
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Bleomycin + Ruxolitinib
|
DC1WLTD
|
Bleomycin
|
Hodgkin lymphoma (Cell Line: HDLM-2)
|
[7] |
|
BMS-536924 + Ruxolitinib
|
DCDA3NZ
|
BMS-536924
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Bortezomib + Ruxolitinib
|
DCKQGQM
|
Bortezomib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Bromhexine + Ruxolitinib
|
DCNPQ8P
|
Bromhexine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Budesonide + Ruxolitinib
|
DC2UOGM
|
Budesonide
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Buparlisib + Ruxolitinib
|
DC7JIUH
|
Buparlisib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
BX-912 + Ruxolitinib
|
DCTI2O6
|
BX-912
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
CA-074Me + Ruxolitinib
|
DC41EUW
|
CA-074Me
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
CA4P + Ruxolitinib
|
DC3Z552
|
CA4P
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
CA4P + Ruxolitinib
|
DC9LTBX
|
CA4P
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Cabazitaxel + Ruxolitinib
|
DC605WF
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: NCIH23)
|
[8] |
|
Cabazitaxel + Ruxolitinib
|
DCB0TLB
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: A549)
|
[8] |
|
Cabazitaxel + Ruxolitinib
|
DCPXRYO
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: SW-620)
|
[8] |
|
Cabazitaxel + Ruxolitinib
|
DCW5E20
|
Cabazitaxel
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Cabazitaxel + Ruxolitinib
|
DCRKI87
|
Cabazitaxel
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[8] |
|
Cabazitaxel + Ruxolitinib
|
DC3YHCX
|
Cabazitaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[8] |
|
Cabazitaxel + Ruxolitinib
|
DCUMT7L
|
Cabazitaxel
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Cabazitaxel + Ruxolitinib
|
DC5PJAZ
|
Cabazitaxel
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[8] |
|
Cabazitaxel + Ruxolitinib
|
DCO0QCI
|
Cabazitaxel
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[8] |
|
Cabazitaxel + Ruxolitinib
|
DCHP5JF
|
Cabazitaxel
|
Colon carcinoma (Cell Line: KM12)
|
[9] |
|
Camptothecin + Ruxolitinib
|
DCUVUW9
|
Camptothecin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
CAP-232 + Ruxolitinib
|
DC8N793
|
CAP-232
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Carisoprodol + Ruxolitinib
|
DCSTXL1
|
Carisoprodol
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
CC-25430 + Ruxolitinib
|
DCYQ0KB
|
CC-25430
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Cefdinir + Ruxolitinib
|
DCS73OZ
|
Cefdinir
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Cerulenin + Ruxolitinib
|
DCQB83C
|
Cerulenin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
CGI-1316 + Ruxolitinib
|
DCPHVLL
|
CGI-1316
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
CHIR-99021 + Ruxolitinib
|
DCUDI3Z
|
CHIR-99021
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
CHS-828 + Ruxolitinib
|
DCWWS4M
|
CHS-828
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Cilostazol + Ruxolitinib
|
DCY214U
|
Cilostazol
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Colchicine + Ruxolitinib
|
DC3CHE1
|
Colchicine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Cortisone acetate + Ruxolitinib
|
DCS5T54
|
Cortisone acetate
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
CP-945598 + Ruxolitinib
|
DCZYEGX
|
CP-945598
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Crizotinib + Ruxolitinib
|
DCUTJVH
|
Crizotinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Crizotinib + Ruxolitinib
|
DCIWZ94
|
Crizotinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[8] |
|
Crizotinib + Ruxolitinib
|
DC8X7JH
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[9] |
|
CUDC-101 + Ruxolitinib
|
DCSR29K
|
CUDC-101
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
CUDC-101 + Ruxolitinib
|
DCB96FK
|
CUDC-101
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
CYCLOPAMINE + Ruxolitinib
|
DCWON88
|
CYCLOPAMINE
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Cytarabine + Ruxolitinib
|
DCUFYVQ
|
Cytarabine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Dactinomycin + Ruxolitinib
|
DCJ9IF0
|
Dactinomycin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Dactinomycin + Ruxolitinib
|
DCW1KPP
|
Dactinomycin
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[7] |
|
Daidzein + Ruxolitinib
|
DCU9VTF
|
Daidzein
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Darunavir + Ruxolitinib
|
DC6S8YC
|
Darunavir
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Delanzomib + Ruxolitinib
|
DC3EU9J
|
Delanzomib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Dexamethasone + Ruxolitinib
|
DC0Y025
|
Dexamethasone
|
Diffuse intrinsic pontine glioma (Cell Line: DIPG25)
|
[8] |
|
Dexamethasone + Ruxolitinib
|
DCDSBJ6
|
Dexamethasone
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Dexamethasone + Ruxolitinib
|
DCT996C
|
Dexamethasone
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Dexamethasone + Ruxolitinib
|
DCVF007
|
Dexamethasone
|
Hodgkin lymphoma (Cell Line: HDLM-2)
|
[7] |
|
Dexamethasone + Ruxolitinib
|
DC4Q1KC
|
Dexamethasone
|
Hodgkin lymphoma (Cell Line: L-428)
|
[7] |
|
Dioscin + Ruxolitinib
|
DC2HNQ5
|
Dioscin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Diosmin + Ruxolitinib
|
DCOX3K6
|
Diosmin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Dipyridamole + Ruxolitinib
|
DC5L20R
|
Dipyridamole
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Docetaxel + Ruxolitinib
|
DCEKTQD
|
Docetaxel
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Doxorubicin + Ruxolitinib
|
DCXCLA6
|
Doxorubicin
|
Hodgkin lymphoma (Cell Line: HDLM-2)
|
[8] |
|
Doxorubicin + Ruxolitinib
|
DCTC2FI
|
Doxorubicin
|
Hodgkin lymphoma (Cell Line: L-428)
|
[8] |
|
Doxorubicin + Ruxolitinib
|
DCY532Y
|
Doxorubicin
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Drospirenone + Ruxolitinib
|
DC8X4HN
|
Drospirenone
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Dutasteride + Ruxolitinib
|
DCVHHGC
|
Dutasteride
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Elesclomol + Ruxolitinib
|
DCRYDJ0
|
Elesclomol
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Eltanexor oral + Ruxolitinib
|
DCBH1FM
|
Eltanexor oral
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Encequidar + Ruxolitinib
|
DC901DM
|
Encequidar
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Epirubicin + Ruxolitinib
|
DCLKWG5
|
Epirubicin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[8] |
|
Epirubicin + Ruxolitinib
|
DC5P7FW
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[8] |
|
Epirubicin + Ruxolitinib
|
DCYHN9Z
|
Epirubicin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[8] |
|
Epirubicin + Ruxolitinib
|
DCGT9GO
|
Epirubicin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Epirubicin + Ruxolitinib
|
DCGKPSU
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Epirubicin + Ruxolitinib
|
DC4QV1F
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Epirubicin + Ruxolitinib
|
DCMMTBJ
|
Epirubicin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[7] |
|
Epirubicin + Ruxolitinib
|
DC1GCN6
|
Epirubicin
|
Adenocarcinoma (Cell Line: A549)
|
[7] |
|
Epirubicin + Ruxolitinib
|
DC6LUMS
|
Epirubicin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[7] |
|
Epirubicin + Ruxolitinib
|
DCMCNP2
|
Epirubicin
|
Adenocarcinoma (Cell Line: HCT116)
|
[7] |
|
Epirubicin + Ruxolitinib
|
DCTB8V4
|
Epirubicin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Epirubicin + Ruxolitinib
|
DC1X09O
|
Epirubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[7] |
|
Epirubicin + Ruxolitinib
|
DCU4U2O
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Epirubicin + Ruxolitinib
|
DC5I6J1
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[7] |
|
Epirubicin + Ruxolitinib
|
DC8UW91
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[7] |
|
Epirubicin + Ruxolitinib
|
DC8U3OK
|
Epirubicin
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Epirubicin + Ruxolitinib
|
DCT65LB
|
Epirubicin
|
Melanoma (Cell Line: UACC-257)
|
[7] |
|
Epirubicin + Ruxolitinib
|
DCC67VS
|
Epirubicin
|
Melanoma (Cell Line: MALME-3M)
|
[7] |
|
Epothilone A + Ruxolitinib
|
DCPBRGX
|
Epothilone A
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Epothilone D + Ruxolitinib
|
DCW1ALH
|
Epothilone D
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Epothilone D + Ruxolitinib
|
DCXVLNU
|
Epothilone D
|
Hodgkin lymphoma (Cell Line: HDLM-2)
|
[7] |
|
Epothilone D + Ruxolitinib
|
DCGNFTJ
|
Epothilone D
|
Hodgkin lymphoma (Cell Line: U-HO1)
|
[7] |
|
Evacetrapib + Ruxolitinib
|
DCM488W
|
Evacetrapib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Everolimus + Ruxolitinib
|
DCBF92V
|
Everolimus
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Exatecan + Ruxolitinib
|
DCW090B
|
Exatecan
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Exherin + Ruxolitinib
|
DCJDFU2
|
Exherin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Ezetimibe + Ruxolitinib
|
DCK2Q5D
|
Ezetimibe
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Fascaplysin + Ruxolitinib
|
DCX8OLE
|
Fascaplysin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Flavopiridol + Ruxolitinib
|
DCNXIFM
|
Flavopiridol
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Fluconazole + Ruxolitinib
|
DC1UHAH
|
Fluconazole
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Fludarabine + Ruxolitinib
|
DCUPM6R
|
Fludarabine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Fluocinolone acetonide + Ruxolitinib
|
DCID2PB
|
Fluocinolone acetonide
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Fluticasone propionate + Ruxolitinib
|
DCEOXXO
|
Fluticasone propionate
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
FP-187 + Ruxolitinib
|
DCQJP70
|
FP-187
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
GDC-0077 + Ruxolitinib
|
DCV35SF
|
GDC-0077
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
GDC-0084 + Ruxolitinib
|
DC9NGQ2
|
GDC-0084
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
GDC-0084 + Ruxolitinib
|
DCT2GMU
|
GDC-0084
|
Hodgkin lymphoma (Cell Line: HDLM-2)
|
[7] |
|
GDC-0980/RG7422 + Ruxolitinib
|
DCKCEHG
|
GDC-0980/RG7422
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
GDC-0980/RG7422 + Ruxolitinib
|
DC3M1T3
|
GDC-0980/RG7422
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Gemcitabine + Ruxolitinib
|
DCNWB2P
|
Gemcitabine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Gemcitabine + Ruxolitinib
|
DCFR80Q
|
Gemcitabine
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Gestodene + Ruxolitinib
|
DCVT3XD
|
Gestodene
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
GINKGOLIDE A + Ruxolitinib
|
DCA2L25
|
GINKGOLIDE A
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
GR-159897 + Ruxolitinib
|
DCIZ53I
|
GR-159897
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
GRT-6005 + Ruxolitinib
|
DC7IS7R
|
GRT-6005
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
GSK1016790A + Ruxolitinib
|
DCQSBA1
|
GSK1016790A
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
GSK1070916 + Ruxolitinib
|
DC48E6S
|
GSK1070916
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
GSK2126458 + Ruxolitinib
|
DCQWOC7
|
GSK2126458
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
GSK269962A + Ruxolitinib
|
DC9EXUK
|
GSK269962A
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
GSK461364 + Ruxolitinib
|
DCD42HA
|
GSK461364
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
GSK525762 + Ruxolitinib
|
DCPMM2G
|
GSK525762
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
HKI-272 + Ruxolitinib
|
DCPFKL6
|
HKI-272
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Hyodeoxycholic acid + Ruxolitinib
|
DC763E5
|
Hyodeoxycholic acid
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Ibutilide + Ruxolitinib
|
DCDR16U
|
Ibutilide
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Idelalisib + Ruxolitinib
|
DCCML2I
|
Idelalisib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
IDP-123 + Ruxolitinib
|
DC6NZAQ
|
IDP-123
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
IMD-0354 + Ruxolitinib
|
DC87B0C
|
IMD-0354
|
Hodgkin lymphoma (Cell Line: HDLM-2)
|
[7] |
|
Indazole derivative 5 + Ruxolitinib
|
DCX3BWJ
|
Indazole derivative 5
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[8] |
|
Indazole derivative 5 + Ruxolitinib
|
DCPNMGQ
|
Indazole derivative 5
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Indazole derivative 5 + Ruxolitinib
|
DCO4U0N
|
Indazole derivative 5
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Indazole derivative 5 + Ruxolitinib
|
DCAFVBT
|
Indazole derivative 5
|
Colon carcinoma (Cell Line: KM12)
|
[9] |
|
Indazole derivative 5 + Ruxolitinib
|
DCPKVRD
|
Indazole derivative 5
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Indazole derivative 5 + Ruxolitinib
|
DCAJ1J1
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[7] |
|
Indazole derivative 5 + Ruxolitinib
|
DCA99Z9
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: HT29)
|
[7] |
|
Indazole derivative 5 + Ruxolitinib
|
DCGGSSH
|
Indazole derivative 5
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[7] |
|
Indazole derivative 5 + Ruxolitinib
|
DCZTDP6
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Indazole derivative 5 + Ruxolitinib
|
DCOCUF1
|
Indazole derivative 5
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[7] |
|
Indazole derivative 5 + Ruxolitinib
|
DCCS6FG
|
Indazole derivative 5
|
Melanoma (Cell Line: MALME-3M)
|
[7] |
|
Indazole derivative 5 + Ruxolitinib
|
DCIGYFX
|
Indazole derivative 5
|
Melanoma (Cell Line: UACC-257)
|
[7] |
|
Indazole derivative 5 + Ruxolitinib
|
DCDNMXF
|
Indazole derivative 5
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Indazole derivative 5 + Ruxolitinib
|
DC9ELFW
|
Indazole derivative 5
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[7] |
|
Indazole derivative 5 + Ruxolitinib
|
DC97U96
|
Indazole derivative 5
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[7] |
|
Indirubin deriv. 8a + Ruxolitinib
|
DCVB216
|
Indirubin deriv. 8a
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Ispinesib + Ruxolitinib
|
DC8DQEY
|
Ispinesib
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Ispinesib + Ruxolitinib
|
DCK5Y88
|
Ispinesib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Ispinesib + Ruxolitinib
|
DC7J0TH
|
Ispinesib
|
Hodgkin lymphoma (Cell Line: HDLM-2)
|
[7] |
|
Isradipine + Ruxolitinib
|
DCK8ML3
|
Isradipine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
IT-141 + Ruxolitinib
|
DCIUQ35
|
IT-141
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Itraconazole + Ruxolitinib
|
DCCOP01
|
Itraconazole
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Ivacaftor + Ruxolitinib
|
DCHJLUQ
|
Ivacaftor
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Ixazomib + Ruxolitinib
|
DC274MQ
|
Ixazomib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
JZL195 + Ruxolitinib
|
DCXVVUE
|
JZL195
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
K00244 + Ruxolitinib
|
DC02W0U
|
K00244
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Ki16425 + Ruxolitinib
|
DCQSJ05
|
Ki16425
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Kinetin + Ruxolitinib
|
DCSYD1I
|
Kinetin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
KN-93 + Ruxolitinib
|
DCZMYXH
|
KN-93
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
L-thyroxine + Ruxolitinib
|
DC0GTWT
|
L-thyroxine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Lactulose + Ruxolitinib
|
DCDB4JA
|
Lactulose
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Letrozole + Ruxolitinib
|
DC8P1EX
|
Letrozole
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Lexibulin + Ruxolitinib
|
DCPSCGS
|
Lexibulin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
LGK974 + Ruxolitinib
|
DCFGM5S
|
LGK974
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Licofelone + Ruxolitinib
|
DC3YNTG
|
Licofelone
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Lucanthone + Ruxolitinib
|
DCYRLAY
|
Lucanthone
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
LY2523355 + Ruxolitinib
|
DCTN8DQ
|
LY2523355
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
LY2603618 + Ruxolitinib
|
DCZ29US
|
LY2603618
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Marizomib + Ruxolitinib
|
DCZSCS1
|
Marizomib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Mebendazole + Ruxolitinib
|
DC2QKEF
|
Mebendazole
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Meclinertant + Ruxolitinib
|
DCVJ7CY
|
Meclinertant
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Meprednisone + Ruxolitinib
|
DCBSUXR
|
Meprednisone
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
MG-132 + Ruxolitinib
|
DCF9N4G
|
MG-132
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
MG149 + Ruxolitinib
|
DC35M6G
|
MG149
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Midostaurin + Ruxolitinib
|
DCP5M72
|
Midostaurin
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Mitomycin + Ruxolitinib
|
DC1G2JB
|
Mitomycin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Mitomycin + Ruxolitinib
|
DCHZ431
|
Mitomycin
|
Hodgkin lymphoma (Cell Line: HDLM-2)
|
[7] |
|
MK-2206 + Ruxolitinib
|
DC5I81T
|
MK-2206
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
MK-8245 + Ruxolitinib
|
DCAAXF4
|
MK-8245
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
MLN-120B + Ruxolitinib
|
DC7925R
|
MLN-120B
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
MLN8237 + Ruxolitinib
|
DCB3YZD
|
MLN8237
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
MSC1936369B + Ruxolitinib
|
DCD6ACV
|
MSC1936369B
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Naltrexone + Ruxolitinib
|
DCE3WGJ
|
Naltrexone
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Nedaplatin + Ruxolitinib
|
DCRMT9O
|
Nedaplatin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Nevirapine + Ruxolitinib
|
DCWT0SC
|
Nevirapine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Nilotinib + Ruxolitinib
|
DCN4BCE
|
Nilotinib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Nintedanib + Ruxolitinib
|
DCZMUVN
|
Nintedanib
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
NSC-663284 + Ruxolitinib
|
DC1X5IA
|
NSC-663284
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
NU-6027 + Ruxolitinib
|
DCWON8M
|
NU-6027
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
NVP-AUY922 + Ruxolitinib
|
DCJI23E
|
NVP-AUY922
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
NVP-LAQ824 + Ruxolitinib
|
DC7AEVA
|
NVP-LAQ824
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
NVP-TAE684 + Ruxolitinib
|
DCLAQLH
|
NVP-TAE684
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[7] |
|
Olaparib + Ruxolitinib
|
DCN4OHK
|
Olaparib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Omacetaxine mepesuccinate + Ruxolitinib
|
DCPLMX8
|
Omacetaxine mepesuccinate
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Ombrabulin + Ruxolitinib
|
DCDYIQV
|
Ombrabulin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Ondansetron + Ruxolitinib
|
DCLA1QF
|
Ondansetron
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Oprozomib + Ruxolitinib
|
DCJMRQP
|
Oprozomib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
OSI-027 + Ruxolitinib
|
DC5H6WN
|
OSI-027
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
OSI-930 + Ruxolitinib
|
DCQWT3V
|
OSI-930
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Ospemifene + Ruxolitinib
|
DCV3UD5
|
Ospemifene
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
OTX-015 + Ruxolitinib
|
DCJ4B8X
|
OTX-015
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Paeoniflorin + Ruxolitinib
|
DC0JKUD
|
Paeoniflorin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
PD-0173955 + Ruxolitinib
|
DCWR1XM
|
PD-0173955
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Pefloxacin + Ruxolitinib
|
DCK2GT8
|
Pefloxacin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Pentamidine + Ruxolitinib
|
DCLGKSK
|
Pentamidine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Perhexiline + Ruxolitinib
|
DCNCVAE
|
Perhexiline
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
PF-03772304 + Ruxolitinib
|
DCCZVUG
|
PF-03772304
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
PF-03772304 + Ruxolitinib
|
DCCRSR2
|
PF-03772304
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
PF-03814735 + Ruxolitinib
|
DCBHUXE
|
PF-03814735
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
PF-04691502 + Ruxolitinib
|
DCIRMNC
|
PF-04691502
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
PF-05212384 + Ruxolitinib
|
DCU5B0S
|
PF-05212384
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
PF-3758309 + Ruxolitinib
|
DCL4ERT
|
PF-3758309
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
PF-4217903 + Ruxolitinib
|
DCCA900
|
PF-4217903
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
PF3845 + Ruxolitinib
|
DCB8W5E
|
PF3845
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
PHA-690509 + Ruxolitinib
|
DCCKBMR
|
PHA-690509
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Phenelzine + Ruxolitinib
|
DCWDGX2
|
Phenelzine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Phlorizin + Ruxolitinib
|
DCU31U0
|
Phlorizin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
PIK-75 + Ruxolitinib
|
DCYOP5J
|
PIK-75
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
PIPERINE + Ruxolitinib
|
DCES1AK
|
PIPERINE
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
PK 11195 + Ruxolitinib
|
DC23TN8
|
PK 11195
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Plicamycin + Ruxolitinib
|
DCZ3T7Z
|
Plicamycin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Plinabulin + Ruxolitinib
|
DC1ZL13
|
Plinabulin
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Plinabulin + Ruxolitinib
|
DCR5UI8
|
Plinabulin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
PMID26394986-Compound-43 + Ruxolitinib
|
DCPOLMW
|
PMID26394986-Compound-43
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
PMID26394986-Compound-43 + Ruxolitinib
|
DCX498D
|
PMID26394986-Compound-43
|
Hodgkin lymphoma (Cell Line: HDLM-2)
|
[7] |
|
PMID28460551-Compound-2 + Ruxolitinib
|
DCWF791
|
PMID28460551-Compound-2
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Podofilox + Ruxolitinib
|
DCNWSTB
|
Podofilox
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Podofilox + Ruxolitinib
|
DCS5PVC
|
Podofilox
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Pracinostat + Ruxolitinib
|
DCV52O4
|
Pracinostat
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Pracinostat + Ruxolitinib
|
DCKZET2
|
Pracinostat
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
PRAVADOLINE + Ruxolitinib
|
DCC4WFL
|
PRAVADOLINE
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Prednisone + Ruxolitinib
|
DCG9TTD
|
Prednisone
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Pyronaridine + Ruxolitinib
|
DCAGCC8
|
Pyronaridine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Pyroxamide + Ruxolitinib
|
DC0V4EP
|
Pyroxamide
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
R-roscovitine + Ruxolitinib
|
DCVGMZ8
|
R-roscovitine
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
RAF265 + Ruxolitinib
|
DCUUQK6
|
RAF265
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Raloxifene + Ruxolitinib
|
DC7BQDC
|
Raloxifene
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Raloxifene + Ruxolitinib
|
DCEA411
|
Raloxifene
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[8] |
|
Raloxifene + Ruxolitinib
|
DCVE39C
|
Raloxifene
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Raloxifene + Ruxolitinib
|
DC7NBH6
|
Raloxifene
|
Adenocarcinoma (Cell Line: HCT-15)
|
[7] |
|
Raloxifene + Ruxolitinib
|
DC8ZEQ8
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Raloxifene + Ruxolitinib
|
DC9DYXW
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[7] |
|
Raloxifene + Ruxolitinib
|
DCXJ9RK
|
Raloxifene
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[7] |
|
Raloxifene + Ruxolitinib
|
DC65DRT
|
Raloxifene
|
Melanoma (Cell Line: MALME-3M)
|
[7] |
|
Raloxifene + Ruxolitinib
|
DCE6LFB
|
Raloxifene
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[7] |
|
Raloxifene + Ruxolitinib
|
DC4SVVR
|
Raloxifene
|
Prostate carcinoma (Cell Line: PC-3)
|
[7] |
|
Riboflavin + Ruxolitinib
|
DCI68CB
|
Riboflavin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Riociguat + Ruxolitinib
|
DC1G2GO
|
Riociguat
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Rottlerin + Ruxolitinib
|
DC88AHO
|
Rottlerin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Roxithromycin + Ruxolitinib
|
DCX7GHC
|
Roxithromycin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
RTB101 + Ruxolitinib
|
DC265RO
|
RTB101
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
RTB101 + Ruxolitinib
|
DCQ7H9K
|
RTB101
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Rupintrivir + Ruxolitinib
|
DCHPWGW
|
Rupintrivir
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Ruxolitinib + Mechlorethamine
|
DCRCT2J
|
Mechlorethamine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[8] |
|
Ruxolitinib + Mechlorethamine
|
DCDAAOJ
|
Mechlorethamine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Mechlorethamine
|
DC0M3D3
|
Mechlorethamine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + Pentostatin
|
DCGJJ9S
|
Pentostatin
|
Glioma (Cell Line: SF-268)
|
[8] |
|
Ruxolitinib + Pentostatin
|
DC82ARE
|
Pentostatin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + Fulvestrant
|
DCPCZZH
|
Fulvestrant
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Fulvestrant
|
DCD37IY
|
Fulvestrant
|
Glioma (Cell Line: SF-268)
|
[8] |
|
Ruxolitinib + Gefitinib
|
DCRYTUH
|
Gefitinib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[8] |
|
Ruxolitinib + Gefitinib
|
DCQ8WK8
|
Gefitinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Gefitinib
|
DCQKW7W
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[8] |
|
Ruxolitinib + Gefitinib
|
DCUX7F9
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[8] |
|
Ruxolitinib + Gefitinib
|
DCLBMRG
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[8] |
|
Ruxolitinib + Gefitinib
|
DCB831U
|
Gefitinib
|
Glioma (Cell Line: SF-268)
|
[8] |
|
Ruxolitinib + Ixabepilone
|
DCQDB17
|
Ixabepilone
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[8] |
|
Ruxolitinib + Ixabepilone
|
DCQ2429
|
Ixabepilone
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Ixabepilone
|
DC46XTQ
|
Ixabepilone
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[8] |
|
Ruxolitinib + Ixabepilone
|
DC25Q0Y
|
Ixabepilone
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[8] |
|
Ruxolitinib + Ixabepilone
|
DCY0EDM
|
Ixabepilone
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[8] |
|
Ruxolitinib + Dactinomycin
|
DCUN6X7
|
Dactinomycin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[8] |
|
Ruxolitinib + Dactinomycin
|
DCXPMFW
|
Dactinomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Dactinomycin
|
DCV8TVH
|
Dactinomycin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[8] |
|
Ruxolitinib + Dactinomycin
|
DCHL303
|
Dactinomycin
|
Astrocytoma (Cell Line: U251)
|
[8] |
|
Ruxolitinib + Dactinomycin
|
DC5TDR0
|
Dactinomycin
|
Astrocytoma (Cell Line: SNB-19)
|
[8] |
|
Ruxolitinib + Dactinomycin
|
DCACAS8
|
Dactinomycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[8] |
|
Ruxolitinib + Dactinomycin
|
DCAX5P2
|
Dactinomycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Dactinomycin
|
DCPWW8O
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[8] |
|
Ruxolitinib + Dactinomycin
|
DCGKKD8
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[8] |
|
Ruxolitinib + Dactinomycin
|
DC0ESKV
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[8] |
|
Ruxolitinib + Dactinomycin
|
DC3OQMB
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[8] |
|
Ruxolitinib + Dactinomycin
|
DC3HMNO
|
Dactinomycin
|
Glioblastoma (Cell Line: SNB-75)
|
[8] |
|
Ruxolitinib + Dactinomycin
|
DCXEIXA
|
Dactinomycin
|
Glioma (Cell Line: SF-295)
|
[8] |
|
Ruxolitinib + Dactinomycin
|
DCDSKZT
|
Dactinomycin
|
Glioma (Cell Line: SF-268)
|
[8] |
|
Ruxolitinib + Dactinomycin
|
DCL8P09
|
Dactinomycin
|
Glioma (Cell Line: SF-539)
|
[8] |
|
Ruxolitinib + Dactinomycin
|
DCIEFCO
|
Dactinomycin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[8] |
|
Ruxolitinib + Dactinomycin
|
DCYGOX2
|
Dactinomycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + Dactinomycin
|
DCUGW9W
|
Dactinomycin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[8] |
|
Ruxolitinib + DFN-15
|
DCVX78B
|
DFN-15
|
Glioma (Cell Line: SF-268)
|
[8] |
|
Ruxolitinib + DFN-15
|
DC1CT0U
|
DFN-15
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + Lapatinib
|
DCHG466
|
Lapatinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + Crizotinib
|
DC36MUF
|
Crizotinib
|
Astrocytoma (Cell Line: U251)
|
[8] |
|
Ruxolitinib + Crizotinib
|
DCR5S6Y
|
Crizotinib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[8] |
|
Ruxolitinib + Cyclophosphamide
|
DCYGXLJ
|
Cyclophosphamide
|
Astrocytoma (Cell Line: U251)
|
[8] |
|
Ruxolitinib + LIAROZOLE
|
DCKOVJY
|
LIAROZOLE
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[8] |
|
Ruxolitinib + Vismodegib
|
DCOWO9T
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[8] |
|
Ruxolitinib + Vismodegib
|
DCW8GW4
|
Vismodegib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + Isoniazid
|
DCT2NPX
|
Isoniazid
|
Astrocytoma (Cell Line: U251)
|
[8] |
|
Ruxolitinib + Isoniazid
|
DCGUYDF
|
Isoniazid
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[8] |
|
Ruxolitinib + Isoniazid
|
DCKKBVG
|
Isoniazid
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[8] |
|
Ruxolitinib + Isoniazid
|
DC15CGY
|
Isoniazid
|
Glioma (Cell Line: SF-539)
|
[8] |
|
Ruxolitinib + Isoniazid
|
DCYHQGZ
|
Isoniazid
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + Arsenic trioxide
|
DCQO5OD
|
Arsenic trioxide
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[8] |
|
Ruxolitinib + Lenalidomide
|
DC03VCP
|
Lenalidomide
|
Glioma (Cell Line: SF-268)
|
[8] |
|
Ruxolitinib + Plicamycin
|
DCAK2AJ
|
Plicamycin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[8] |
|
Ruxolitinib + Plicamycin
|
DCVQCXX
|
Plicamycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Plicamycin
|
DC7I3LT
|
Plicamycin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[8] |
|
Ruxolitinib + Plicamycin
|
DCMRJUI
|
Plicamycin
|
Astrocytoma (Cell Line: U251)
|
[8] |
|
Ruxolitinib + Plicamycin
|
DCP0UVE
|
Plicamycin
|
Astrocytoma (Cell Line: SNB-19)
|
[8] |
|
Ruxolitinib + Plicamycin
|
DCSZ29A
|
Plicamycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[8] |
|
Ruxolitinib + Plicamycin
|
DCT8TVE
|
Plicamycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Plicamycin
|
DCMGNCV
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[8] |
|
Ruxolitinib + Plicamycin
|
DCYJKW4
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[8] |
|
Ruxolitinib + Plicamycin
|
DC0MDOV
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[8] |
|
Ruxolitinib + Plicamycin
|
DCN1A5J
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[8] |
|
Ruxolitinib + Plicamycin
|
DCFUV3H
|
Plicamycin
|
Glioma (Cell Line: SF-539)
|
[8] |
|
Ruxolitinib + Plicamycin
|
DCOXTVC
|
Plicamycin
|
Glioma (Cell Line: SF-295)
|
[8] |
|
Ruxolitinib + Plicamycin
|
DCFL78I
|
Plicamycin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[8] |
|
Ruxolitinib + Plicamycin
|
DC46V0X
|
Plicamycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + Nilotinib
|
DCKZ839
|
Nilotinib
|
Astrocytoma (Cell Line: SNB-19)
|
[8] |
|
Ruxolitinib + Nilotinib
|
DCUKJY9
|
Nilotinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Nilotinib
|
DCW15JY
|
Nilotinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[8] |
|
Ruxolitinib + Nilotinib
|
DCERLNP
|
Nilotinib
|
Glioma (Cell Line: SF-539)
|
[8] |
|
Ruxolitinib + Thioguanine
|
DCQLJ3S
|
Thioguanine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Thioguanine
|
DC0UB9C
|
Thioguanine
|
Astrocytoma (Cell Line: SNB-19)
|
[8] |
|
Ruxolitinib + Thioguanine
|
DCIMAZ1
|
Thioguanine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Thioguanine
|
DCWRIIN
|
Thioguanine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[8] |
|
Ruxolitinib + Thioguanine
|
DC4O4IJ
|
Thioguanine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[8] |
|
Ruxolitinib + Thioguanine
|
DCDD9GJ
|
Thioguanine
|
Glioma (Cell Line: SF-295)
|
[8] |
|
Ruxolitinib + Thioguanine
|
DC62QJ5
|
Thioguanine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[8] |
|
Ruxolitinib + Thioguanine
|
DCPOKV3
|
Thioguanine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[8] |
|
Ruxolitinib + Triapine
|
DCGV4F8
|
Triapine
|
Glioma (Cell Line: SF-268)
|
[8] |
|
Ruxolitinib + ABIRATERONE
|
DCMRNHR
|
ABIRATERONE
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[8] |
|
Ruxolitinib + 10-hydroxycamptothecin
|
DCV4SPO
|
10-hydroxycamptothecin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[8] |
|
Ruxolitinib + 10-hydroxycamptothecin
|
DCXZK8U
|
10-hydroxycamptothecin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Topetecan
|
DCU01CA
|
Topetecan
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Topetecan
|
DCLH1C1
|
Topetecan
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[8] |
|
Ruxolitinib + Amonafide
|
DCGNAYU
|
Amonafide
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Amonafide
|
DCTUOO4
|
Amonafide
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[8] |
|
Ruxolitinib + Amonafide
|
DCG7ZW4
|
Amonafide
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[8] |
|
Ruxolitinib + Pralatrexate
|
DCNUJLZ
|
Pralatrexate
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[8] |
|
Ruxolitinib + Terameprocol
|
DCRLHHF
|
Terameprocol
|
Astrocytoma (Cell Line: U251)
|
[8] |
|
Ruxolitinib + Terameprocol
|
DC05N6P
|
Terameprocol
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[8] |
|
Ruxolitinib + Terameprocol
|
DCRBJDD
|
Terameprocol
|
Glioma (Cell Line: SF-268)
|
[8] |
|
Ruxolitinib + SCH 727965
|
DCDBXVA
|
SCH 727965
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + SCH 727965
|
DCPD9RD
|
SCH 727965
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[8] |
|
Ruxolitinib + SCH 727965
|
DC9YTRL
|
SCH 727965
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Ifosfamide
|
DCVOMA8
|
Ifosfamide
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[8] |
|
Ruxolitinib + Ifosfamide
|
DC2080A
|
Ifosfamide
|
Glioma (Cell Line: SF-268)
|
[8] |
|
Ruxolitinib + Ifosfamide
|
DCOWOMQ
|
Ifosfamide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + Dexrazoxane
|
DCSKAIL
|
Dexrazoxane
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Dexrazoxane
|
DCCNYBA
|
Dexrazoxane
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[8] |
|
Ruxolitinib + Docetaxel
|
DCCJ9LQ
|
Docetaxel
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Docetaxel
|
DCWV2GP
|
Docetaxel
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Docetaxel
|
DCH8LKG
|
Docetaxel
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[8] |
|
Ruxolitinib + Raloxifene
|
DCOTO11
|
Raloxifene
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[8] |
|
Ruxolitinib + Raloxifene
|
DCTP4ZN
|
Raloxifene
|
Astrocytoma (Cell Line: SNB-19)
|
[8] |
|
Ruxolitinib + Raloxifene
|
DCOBSOR
|
Raloxifene
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[8] |
|
Ruxolitinib + Raloxifene
|
DCZROOJ
|
Raloxifene
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Raloxifene
|
DCHFQ5Q
|
Raloxifene
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[8] |
|
Ruxolitinib + Raloxifene
|
DCH922I
|
Raloxifene
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[8] |
|
Ruxolitinib + Raloxifene
|
DCGT9LJ
|
Raloxifene
|
Glioma (Cell Line: SF-268)
|
[8] |
|
Ruxolitinib + Raloxifene
|
DCR0R09
|
Raloxifene
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DCYIXAC
|
Bendamustine hydrochloride
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[8] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DCV8UUE
|
Bendamustine hydrochloride
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DC0MQNV
|
Bendamustine hydrochloride
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DC72W88
|
Bendamustine hydrochloride
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[8] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DCESEXU
|
Bendamustine hydrochloride
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[8] |
|
Ruxolitinib + Trifluridine
|
DC9ZTDE
|
Trifluridine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Trifluridine
|
DC1RPQY
|
Trifluridine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[8] |
|
Ruxolitinib + Sirolimus
|
DCJEEHT
|
Sirolimus
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Sirolimus
|
DCRF3F9
|
Sirolimus
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[8] |
|
Ruxolitinib + Sirolimus
|
DC3SOIJ
|
Sirolimus
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Sirolimus
|
DCB8TRZ
|
Sirolimus
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[8] |
|
Ruxolitinib + Sirolimus
|
DC8V49W
|
Sirolimus
|
Renal cell carcinoma (Cell Line: UO-31)
|
[8] |
|
Ruxolitinib + Letrozole
|
DC5KUCO
|
Letrozole
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[8] |
|
Ruxolitinib + Letrozole
|
DCP2B22
|
Letrozole
|
Glioma (Cell Line: SF-268)
|
[8] |
|
Ruxolitinib + Letrozole
|
DCDX6HX
|
Letrozole
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + Mitomycin
|
DCVSZEZ
|
Mitomycin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[8] |
|
Ruxolitinib + Mitomycin
|
DCUJJJO
|
Mitomycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[8] |
|
Ruxolitinib + SY-1425
|
DC1D4YS
|
SY-1425
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[8] |
|
Ruxolitinib + SY-1425
|
DCITECP
|
SY-1425
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + SY-1425
|
DC84DFM
|
SY-1425
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[8] |
|
Ruxolitinib + Uracil mustard
|
DCSVVHE
|
Uracil mustard
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Uracil mustard
|
DC01PP6
|
Uracil mustard
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Uracil mustard
|
DCAODFZ
|
Uracil mustard
|
Glioma (Cell Line: SF-295)
|
[8] |
|
Ruxolitinib + Arfolitixorin
|
DCYIAYN
|
Arfolitixorin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Arfolitixorin
|
DCDC6RB
|
Arfolitixorin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[8] |
|
Ruxolitinib + Arfolitixorin
|
DCV6K4T
|
Arfolitixorin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[8] |
|
Ruxolitinib + BIO-300
|
DCUIRX3
|
BIO-300
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + BIO-300
|
DC2P74V
|
BIO-300
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + BIO-300
|
DCVYSSU
|
BIO-300
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[8] |
|
Ruxolitinib + BIO-300
|
DC4PF2V
|
BIO-300
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[8] |
|
Ruxolitinib + Altretamine
|
DCNOVLZ
|
Altretamine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[8] |
|
Ruxolitinib + Altretamine
|
DC1MHL3
|
Altretamine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Altretamine
|
DC2JSB1
|
Altretamine
|
Astrocytoma (Cell Line: SNB-19)
|
[8] |
|
Ruxolitinib + Altretamine
|
DCOW5N2
|
Altretamine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[8] |
|
Ruxolitinib + Altretamine
|
DCR3SZ1
|
Altretamine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Altretamine
|
DCD6CAV
|
Altretamine
|
Glioma (Cell Line: SF-268)
|
[8] |
|
Ruxolitinib + Altretamine
|
DCBYLK1
|
Altretamine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + Altretamine
|
DC6V8UW
|
Altretamine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[8] |
|
Ruxolitinib + TEM
|
DC4M1QW
|
TEM
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[8] |
|
Ruxolitinib + TEM
|
DC75ILE
|
TEM
|
Glioma (Cell Line: SF-268)
|
[8] |
|
Ruxolitinib + TEM
|
DC7PIVX
|
TEM
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + JNK-IN-8
|
DCUZNS3
|
JNK-IN-8
|
Renal cell carcinoma (Cell Line: SN12C)
|
[8] |
|
Ruxolitinib + Idarubicin
|
DCYP1IP
|
Idarubicin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[8] |
|
Ruxolitinib + Idarubicin
|
DCQU3EL
|
Idarubicin
|
Glioblastoma? (Cell Line: T98G)
|
[8] |
|
Ruxolitinib + Indazole derivative 5
|
DCH6F1J
|
Indazole derivative 5
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Indazole derivative 5
|
DCOCJA0
|
Indazole derivative 5
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[8] |
|
Ruxolitinib + Indazole derivative 5
|
DCS9ZF1
|
Indazole derivative 5
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + Imatinib
|
DCI8JQS
|
Imatinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Bleomycin
|
DCT49AZ
|
Bleomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Bleomycin
|
DC17J7T
|
Bleomycin
|
Astrocytoma (Cell Line: SNB-19)
|
[8] |
|
Ruxolitinib + Bleomycin
|
DCMEO4P
|
Bleomycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Bleomycin
|
DCZ5XTU
|
Bleomycin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[8] |
|
Ruxolitinib + Bortezomib
|
DCN5ER0
|
Bortezomib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[8] |
|
Ruxolitinib + Bortezomib
|
DC7OJX6
|
Bortezomib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Bortezomib
|
DCCJ07B
|
Bortezomib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[8] |
|
Ruxolitinib + Anastrozole
|
DCENKG7
|
Anastrozole
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Dacarbazine
|
DC0S84M
|
Dacarbazine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Dacarbazine
|
DCVU9NV
|
Dacarbazine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[8] |
|
Ruxolitinib + Dacarbazine
|
DCQHXAE
|
Dacarbazine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Dacarbazine
|
DC5QQ81
|
Dacarbazine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[8] |
|
Ruxolitinib + Dacarbazine
|
DC4NRJC
|
Dacarbazine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[8] |
|
Ruxolitinib + Valrubicin
|
DCY3FUN
|
Valrubicin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[8] |
|
Ruxolitinib + Valrubicin
|
DCF6CK5
|
Valrubicin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + Topotecan
|
DC1H4NB
|
Topotecan
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Topotecan
|
DCCFLLS
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[8] |
|
Ruxolitinib + Cabazitaxel
|
DCKPPHB
|
Cabazitaxel
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Cabazitaxel
|
DCU378U
|
Cabazitaxel
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[8] |
|
Ruxolitinib + Cabazitaxel
|
DC6EGAQ
|
Cabazitaxel
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[8] |
|
Ruxolitinib + Epirubicin
|
DCJY38I
|
Epirubicin
|
Astrocytoma (Cell Line: U251)
|
[8] |
|
Ruxolitinib + Epirubicin
|
DCJBRMD
|
Epirubicin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[8] |
|
Ruxolitinib + Epirubicin
|
DCHFUE6
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[8] |
|
Ruxolitinib + Epirubicin
|
DCT437T
|
Epirubicin
|
Glioblastoma (Cell Line: SNB-75)
|
[8] |
|
Ruxolitinib + Epirubicin
|
DCYURE8
|
Epirubicin
|
Glioma (Cell Line: SF-539)
|
[8] |
|
Ruxolitinib + Epirubicin
|
DCY350T
|
Epirubicin
|
Glioma (Cell Line: SF-268)
|
[8] |
|
Ruxolitinib + Epirubicin
|
DCNH4QN
|
Epirubicin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[8] |
|
Ruxolitinib + Epirubicin
|
DCVCP7F
|
Epirubicin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + Cisplatin
|
DC219XZ
|
Cisplatin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[8] |
|
Ruxolitinib + Cisplatin
|
DC3QMRX
|
Cisplatin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Cisplatin
|
DCORE6X
|
Cisplatin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[8] |
|
Ruxolitinib + Cisplatin
|
DCON1DE
|
Cisplatin
|
Astrocytoma (Cell Line: SNB-19)
|
[8] |
|
Ruxolitinib + Cisplatin
|
DCNAKGS
|
Cisplatin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[8] |
|
Ruxolitinib + Cisplatin
|
DC6NGA2
|
Cisplatin
|
Glioma (Cell Line: SF-268)
|
[8] |
|
Ruxolitinib + Cisplatin
|
DC6GRZ2
|
Cisplatin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + Romidepsin
|
DCNYLM3
|
Romidepsin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Azacitidine
|
DCY451E
|
Azacitidine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Azacitidine
|
DC25N58
|
Azacitidine
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[8] |
|
Ruxolitinib + Pomalidomide
|
DCQENQW
|
Pomalidomide
|
Astrocytoma (Cell Line: U251)
|
[8] |
|
Ruxolitinib + Pomalidomide
|
DCOTYOT
|
Pomalidomide
|
Astrocytoma (Cell Line: SNB-19)
|
[8] |
|
Ruxolitinib + Pomalidomide
|
DCRZLRV
|
Pomalidomide
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[8] |
|
Ruxolitinib + Pomalidomide
|
DC240CF
|
Pomalidomide
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[8] |
|
Ruxolitinib + Pomalidomide
|
DCY9TYY
|
Pomalidomide
|
Glioma (Cell Line: SF-539)
|
[8] |
|
Ruxolitinib + Pomalidomide
|
DCHD379
|
Pomalidomide
|
Glioma (Cell Line: SF-268)
|
[8] |
|
Ruxolitinib + Pomalidomide
|
DCQU349
|
Pomalidomide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + Vinflunine
|
DCK0KQ8
|
Vinflunine
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[8] |
|
Ruxolitinib + Mercaptopurine
|
DCBK5YD
|
Mercaptopurine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[8] |
|
Ruxolitinib + Mercaptopurine
|
DCZAKE6
|
Mercaptopurine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[8] |
|
Ruxolitinib + Mepacrine
|
DCAC9SV
|
Mepacrine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[8] |
|
Ruxolitinib + Mepacrine
|
DCCPZQ0
|
Mepacrine
|
Astrocytoma (Cell Line: SNB-19)
|
[8] |
|
Ruxolitinib + Taxol
|
DCWQ7X1
|
Taxol
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[8] |
|
Ruxolitinib + Taxol
|
DCJWWB6
|
Taxol
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[8] |
|
Ruxolitinib + Taxol
|
DCY2CPL
|
Taxol
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[8] |
|
Ruxolitinib + Fludarabine
|
DCJG2ET
|
Fludarabine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[8] |
|
Ruxolitinib + FORMESTANE
|
DC5GUD4
|
FORMESTANE
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[8] |
|
Ruxolitinib + Estramustine
|
DCR1W0G
|
Estramustine
|
Astrocytoma (Cell Line: SNB-19)
|
[8] |
|
Ruxolitinib + Dasatinib
|
DCUWJ67
|
Dasatinib
|
Astrocytoma (Cell Line: U251)
|
[8] |
|
Ruxolitinib + Dasatinib
|
DCMIKSM
|
Dasatinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[8] |
|
Ruxolitinib + Dasatinib
|
DC9EST0
|
Dasatinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[8] |
|
Ruxolitinib + Dasatinib
|
DCU5R2F
|
Dasatinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[8] |
|
Ruxolitinib + Dasatinib
|
DCJLVNL
|
Dasatinib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[8] |
|
Ruxolitinib + Dasatinib
|
DC2S7YS
|
Dasatinib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[8] |
|
Ruxolitinib + Pentostatin
|
DCM5DSN
|
Pentostatin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Pentostatin
|
DCLJ7V9
|
Pentostatin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[9] |
|
Ruxolitinib + Pentostatin
|
DCZGMOZ
|
Pentostatin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Picoplatin
|
DCJ48VL
|
Picoplatin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[9] |
|
Ruxolitinib + Fulvestrant
|
DC81LPK
|
Fulvestrant
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Fulvestrant
|
DCOI5F1
|
Fulvestrant
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Gefitinib
|
DCV0SIQ
|
Gefitinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Ruxolitinib + Gefitinib
|
DCX83JW
|
Gefitinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Ixabepilone
|
DC76S0G
|
Ixabepilone
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Ruxolitinib + Ixabepilone
|
DCVKFD3
|
Ixabepilone
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Ixabepilone
|
DCX17DK
|
Ixabepilone
|
Colon carcinoma (Cell Line: KM12)
|
[9] |
|
Ruxolitinib + Dactinomycin
|
DC0YWUK
|
Dactinomycin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Ruxolitinib + Dactinomycin
|
DC0YEZJ
|
Dactinomycin
|
Carcinoma (Cell Line: RXF 393)
|
[9] |
|
Ruxolitinib + Dactinomycin
|
DCQ4V01
|
Dactinomycin
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Dactinomycin
|
DCPDJUK
|
Dactinomycin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[9] |
|
Ruxolitinib + Dactinomycin
|
DC0FZIV
|
Dactinomycin
|
Colon carcinoma (Cell Line: KM12)
|
[9] |
|
Ruxolitinib + Dactinomycin
|
DC3VAF3
|
Dactinomycin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + DFN-15
|
DC5BQOZ
|
DFN-15
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + DFN-15
|
DCT455K
|
DFN-15
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + DFN-15
|
DCTR14O
|
DFN-15
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Lapatinib
|
DCGN4GG
|
Lapatinib
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Lapatinib
|
DCF8ZA0
|
Lapatinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Lapatinib
|
DC8F8M6
|
Lapatinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + PMID28460551-Compound-2
|
DC4HBSM
|
PMID28460551-Compound-2
|
Carcinoma (Cell Line: RXF 393)
|
[9] |
|
Ruxolitinib + Crizotinib
|
DCW3TCL
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Crizotinib
|
DCG6BZ6
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Vismodegib
|
DCC6H2Y
|
Vismodegib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Ruxolitinib + Vismodegib
|
DC609OR
|
Vismodegib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Isoniazid
|
DCZFKMQ
|
Isoniazid
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Vemurafenib
|
DCJ0OOS
|
Vemurafenib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Ruxolitinib + Plicamycin
|
DC6XBKU
|
Plicamycin
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Plicamycin
|
DC4G2QL
|
Plicamycin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[9] |
|
Ruxolitinib + Plicamycin
|
DC5BO42
|
Plicamycin
|
Colon carcinoma (Cell Line: KM12)
|
[9] |
|
Ruxolitinib + Plicamycin
|
DC29QEU
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[9] |
|
Ruxolitinib + Plicamycin
|
DCR4RZQ
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Plicamycin
|
DCDFJDH
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Nilotinib
|
DC2B19V
|
Nilotinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Ruxolitinib + Nilotinib
|
DCUJF84
|
Nilotinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Nilotinib
|
DCDCDMB
|
Nilotinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Nilotinib
|
DC1NDMY
|
Nilotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[9] |
|
Ruxolitinib + Thioguanine
|
DCIK0CV
|
Thioguanine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Ruxolitinib + Thioguanine
|
DCT9FT6
|
Thioguanine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Triapine
|
DC6GTPF
|
Triapine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + ABIRATERONE
|
DCZ8OOY
|
ABIRATERONE
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + ABIRATERONE
|
DC3T7HM
|
ABIRATERONE
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[9] |
|
Ruxolitinib + ABIRATERONE
|
DC210W4
|
ABIRATERONE
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Pralatrexate
|
DCZ0G8B
|
Pralatrexate
|
Colon carcinoma (Cell Line: KM12)
|
[9] |
|
Ruxolitinib + Terameprocol
|
DC25VP5
|
Terameprocol
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Terameprocol
|
DCRJM83
|
Terameprocol
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[9] |
|
Ruxolitinib + Terameprocol
|
DCTAS8P
|
Terameprocol
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Terameprocol
|
DCFMMP1
|
Terameprocol
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[9] |
|
Ruxolitinib + SCH 727965
|
DCUOLNB
|
SCH 727965
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Ruxolitinib + SCH 727965
|
DCHXZPU
|
SCH 727965
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Ifosfamide
|
DCZ4OHV
|
Ifosfamide
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Dexrazoxane
|
DCMRCVQ
|
Dexrazoxane
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Docetaxel
|
DCG229J
|
Docetaxel
|
Carcinoma (Cell Line: RXF 393)
|
[9] |
|
Ruxolitinib + Docetaxel
|
DC1LQYC
|
Docetaxel
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Docetaxel
|
DCBTCDR
|
Docetaxel
|
Colon carcinoma (Cell Line: KM12)
|
[9] |
|
Ruxolitinib + Raloxifene
|
DCXKYX3
|
Raloxifene
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Ruxolitinib + Raloxifene
|
DC0HZ18
|
Raloxifene
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Raloxifene
|
DCT2VYQ
|
Raloxifene
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[9] |
|
Ruxolitinib + Raloxifene
|
DC2G93W
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Raloxifene
|
DCFWM6F
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[9] |
|
Ruxolitinib + Raloxifene
|
DCIZZ0L
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DCBJ8PA
|
Bendamustine hydrochloride
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Trifluridine
|
DCIR29V
|
Trifluridine
|
Colon carcinoma (Cell Line: KM12)
|
[9] |
|
Ruxolitinib + Trifluridine
|
DC2P348
|
Trifluridine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Sirolimus
|
DC3Y9K7
|
Sirolimus
|
Carcinoma (Cell Line: RXF 393)
|
[9] |
|
Ruxolitinib + Sirolimus
|
DCA2R9L
|
Sirolimus
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Sirolimus
|
DCSQ5N2
|
Sirolimus
|
Colon carcinoma (Cell Line: KM12)
|
[9] |
|
Ruxolitinib + Sirolimus
|
DCGLT6F
|
Sirolimus
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Letrozole
|
DCJ0PIC
|
Letrozole
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Ruxolitinib + Letrozole
|
DC9SSUQ
|
Letrozole
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Letrozole
|
DCP7V90
|
Letrozole
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Letrozole
|
DC4IWIS
|
Letrozole
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Mitomycin
|
DCQWGZH
|
Mitomycin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Ruxolitinib + Mitomycin
|
DCHAROU
|
Mitomycin
|
Carcinoma (Cell Line: RXF 393)
|
[9] |
|
Ruxolitinib + Mitomycin
|
DC34S3N
|
Mitomycin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Mitomycin
|
DCTGYPT
|
Mitomycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Uracil mustard
|
DCAKPCJ
|
Uracil mustard
|
Colon carcinoma (Cell Line: KM12)
|
[9] |
|
Ruxolitinib + Arfolitixorin
|
DCN7QXA
|
Arfolitixorin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Ruxolitinib + Arfolitixorin
|
DC8J0WW
|
Arfolitixorin
|
Carcinoma (Cell Line: RXF 393)
|
[9] |
|
Ruxolitinib + BIO-300
|
DC4MCGT
|
BIO-300
|
Carcinoma (Cell Line: RXF 393)
|
[9] |
|
Ruxolitinib + BIO-300
|
DC13ZLD
|
BIO-300
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + BIO-300
|
DCE6AFQ
|
BIO-300
|
Colon carcinoma (Cell Line: KM12)
|
[9] |
|
Ruxolitinib + Altretamine
|
DCQIMER
|
Altretamine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Ruxolitinib + Altretamine
|
DC2L4XL
|
Altretamine
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Altretamine
|
DCS7TW6
|
Altretamine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + TEM
|
DCIIMHD
|
TEM
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Ruxolitinib + TEM
|
DC16QFY
|
TEM
|
Carcinoma (Cell Line: RXF 393)
|
[9] |
|
Ruxolitinib + TEM
|
DCJEM8R
|
TEM
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + JNK-IN-8
|
DCV8BAK
|
JNK-IN-8
|
Colon carcinoma (Cell Line: KM12)
|
[9] |
|
Ruxolitinib + Indazole derivative 5
|
DCQWWC4
|
Indazole derivative 5
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Ruxolitinib + Indazole derivative 5
|
DCQ35G4
|
Indazole derivative 5
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[9] |
|
Ruxolitinib + Indazole derivative 5
|
DC33N9Z
|
Indazole derivative 5
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[9] |
|
Ruxolitinib + Imatinib
|
DC5DZ62
|
Imatinib
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Bleomycin
|
DC95FTC
|
Bleomycin
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Bleomycin
|
DCVND6T
|
Bleomycin
|
Colon carcinoma (Cell Line: KM12)
|
[9] |
|
Ruxolitinib + Bortezomib
|
DCVEI9Q
|
Bortezomib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[9] |
|
Ruxolitinib + Bortezomib
|
DCPLPH2
|
Bortezomib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Dacarbazine
|
DC7TMPC
|
Dacarbazine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Ruxolitinib + Dacarbazine
|
DCTTXKS
|
Dacarbazine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Dacarbazine
|
DC0PK6Q
|
Dacarbazine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[9] |
|
Ruxolitinib + Dacarbazine
|
DCEF2E7
|
Dacarbazine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Valrubicin
|
DCUTLJ1
|
Valrubicin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Topotecan
|
DCYK2KA
|
Topotecan
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Topotecan
|
DCGHSW6
|
Topotecan
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Cabazitaxel
|
DCP9IZW
|
Cabazitaxel
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Cabazitaxel
|
DCSGQ8A
|
Cabazitaxel
|
Colon carcinoma (Cell Line: KM12)
|
[9] |
|
Ruxolitinib + Epirubicin
|
DC0MDEV
|
Epirubicin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Ruxolitinib + Epirubicin
|
DC2T6FS
|
Epirubicin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[9] |
|
Ruxolitinib + Epirubicin
|
DC4OPDA
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[9] |
|
Ruxolitinib + Epirubicin
|
DC61QER
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Epirubicin
|
DCOJOF7
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Cisplatin
|
DC2LP6X
|
Cisplatin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Ruxolitinib + Cisplatin
|
DC0PL2Z
|
Cisplatin
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Cisplatin
|
DCDLY8J
|
Cisplatin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[9] |
|
Ruxolitinib + Cisplatin
|
DC0R1FD
|
Cisplatin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Cisplatin
|
DCCTN3M
|
Cisplatin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[9] |
|
Ruxolitinib + Cisplatin
|
DCJ7VG5
|
Cisplatin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Vandetanib
|
DCUO9M9
|
Vandetanib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Ruxolitinib + Vandetanib
|
DCE0TXG
|
Vandetanib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Azacitidine
|
DCUQ9XJ
|
Azacitidine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[9] |
|
Ruxolitinib + Pomalidomide
|
DCO1LKK
|
Pomalidomide
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[9] |
|
Ruxolitinib + Pomalidomide
|
DCIALVE
|
Pomalidomide
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + Pomalidomide
|
DCWTTGN
|
Pomalidomide
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[9] |
|
Ruxolitinib + Taxol
|
DCI9JK1
|
Taxol
|
Carcinoma (Cell Line: RXF 393)
|
[9] |
|
Ruxolitinib + Taxol
|
DCUYCP5
|
Taxol
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Taxol
|
DCNI0Q0
|
Taxol
|
Colon carcinoma (Cell Line: KM12)
|
[9] |
|
Ruxolitinib + Fludarabine
|
DCFT49J
|
Fludarabine
|
Colon carcinoma (Cell Line: KM12)
|
[9] |
|
Ruxolitinib + PMID28870136-Compound-43
|
DCLP9WG
|
PMID28870136-Compound-43
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Ruxolitinib + FORMESTANE
|
DC450B3
|
FORMESTANE
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Estramustine
|
DCCAN5E
|
Estramustine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[9] |
|
Ruxolitinib + Digitoxin
|
DCMF1XI
|
Digitoxin
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Ruxolitinib + Dasatinib
|
DCOHWJT
|
Dasatinib
|
Carcinoma (Cell Line: RXF 393)
|
[9] |
|
Ruxolitinib + Dasatinib
|
DCNEOKG
|
Dasatinib
|
Colon carcinoma (Cell Line: KM12)
|
[9] |
|
Ruxolitinib + Dasatinib
|
DC1RG5H
|
Dasatinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[9] |
|
Ruxolitinib + Mechlorethamine
|
DC0EQCO
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[7] |
|
Ruxolitinib + Mechlorethamine
|
DCIO8UI
|
Mechlorethamine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[7] |
|
Ruxolitinib + Mechlorethamine
|
DC4TFIK
|
Mechlorethamine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[7] |
|
Ruxolitinib + Pentostatin
|
DCO4RBH
|
Pentostatin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[7] |
|
Ruxolitinib + Pentostatin
|
DCXW6O8
|
Pentostatin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Ruxolitinib + Pentostatin
|
DCVXAI4
|
Pentostatin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[7] |
|
Ruxolitinib + Pentostatin
|
DCLAMZI
|
Pentostatin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[7] |
|
Ruxolitinib + Pentostatin
|
DCR7IDY
|
Pentostatin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + Pentostatin
|
DC6N9PD
|
Pentostatin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[7] |
|
Ruxolitinib + Pentostatin
|
DCFJ4NS
|
Pentostatin
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + Pentostatin
|
DCJO7UZ
|
Pentostatin
|
Melanoma (Cell Line: MALME-3M)
|
[7] |
|
Ruxolitinib + Picoplatin
|
DC4121G
|
Picoplatin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[7] |
|
Ruxolitinib + Fulvestrant
|
DCB2OT2
|
Fulvestrant
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[7] |
|
Ruxolitinib + Fulvestrant
|
DCGZV5Z
|
Fulvestrant
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[7] |
|
Ruxolitinib + Fulvestrant
|
DC5PCPA
|
Fulvestrant
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + Fulvestrant
|
DCHF2HM
|
Fulvestrant
|
Melanoma (Cell Line: UACC-257)
|
[7] |
|
Ruxolitinib + Fulvestrant
|
DCD8NGM
|
Fulvestrant
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[7] |
|
Ruxolitinib + Fulvestrant
|
DCJ47YE
|
Fulvestrant
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[7] |
|
Ruxolitinib + Gefitinib
|
DCY3734
|
Gefitinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[7] |
|
Ruxolitinib + Gefitinib
|
DCUUSWP
|
Gefitinib
|
Adenocarcinoma (Cell Line: A549)
|
[7] |
|
Ruxolitinib + Gefitinib
|
DCM0Y09
|
Gefitinib
|
Amelanotic melanoma (Cell Line: M14)
|
[7] |
|
Ruxolitinib + Gefitinib
|
DCXD1ET
|
Gefitinib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Ruxolitinib + Gefitinib
|
DCJ1C7F
|
Gefitinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[7] |
|
Ruxolitinib + Gefitinib
|
DCDAV6W
|
Gefitinib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[7] |
|
Ruxolitinib + Gefitinib
|
DCXM1VV
|
Gefitinib
|
Melanoma (Cell Line: UACC-257)
|
[7] |
|
Ruxolitinib + Gefitinib
|
DCOVCH8
|
Gefitinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[7] |
|
Ruxolitinib + Gefitinib
|
DC0HVPD
|
Gefitinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[7] |
|
Ruxolitinib + Ruxolitinib
|
DCXTM6D
|
Ruxolitinib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Ruxolitinib + Hepzato
|
DCZD8RU
|
Hepzato
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + Hepzato
|
DC4PYW7
|
Hepzato
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[7] |
|
Ruxolitinib + Hepzato
|
DCZ7JYX
|
Hepzato
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[7] |
|
Ruxolitinib + Hepzato
|
DCTUD2U
|
Hepzato
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + Ixabepilone
|
DC2O64X
|
Ixabepilone
|
Adenocarcinoma (Cell Line: SW-620)
|
[7] |
|
Ruxolitinib + Ixabepilone
|
DCDKK7Z
|
Ixabepilone
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[7] |
|
Ruxolitinib + Ixabepilone
|
DCXK5DS
|
Ixabepilone
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[7] |
|
Ruxolitinib + Ixabepilone
|
DC3Z354
|
Ixabepilone
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[7] |
|
Ruxolitinib + Ixabepilone
|
DC8PMKK
|
Ixabepilone
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCA9UBD
|
Dactinomycin
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DC98BFT
|
Dactinomycin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DC8UHXB
|
Dactinomycin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCJKZ68
|
Dactinomycin
|
Adenocarcinoma (Cell Line: A549)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCL0IDF
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCOTGVZ
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCNYL1L
|
Dactinomycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCYGGBT
|
Dactinomycin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCHHLZR
|
Dactinomycin
|
Amelanotic melanoma (Cell Line: M14)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DC12SLQ
|
Dactinomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCJDPZP
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCS32RC
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCXC3D8
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCHBFZS
|
Dactinomycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCLKET4
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCODNRV
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DC9B6Y7
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCCD784
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCZJA7B
|
Dactinomycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCYBU12
|
Dactinomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCYXCXJ
|
Dactinomycin
|
Melanoma (Cell Line: MALME-3M)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCI4XW2
|
Dactinomycin
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCTUQZH
|
Dactinomycin
|
Melanoma (Cell Line: UACC-257)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCCWSQD
|
Dactinomycin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCD413Y
|
Dactinomycin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCFD3KC
|
Dactinomycin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCEYN6C
|
Dactinomycin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCJ8MEE
|
Dactinomycin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[7] |
|
Ruxolitinib + Dactinomycin
|
DCD8TH2
|
Dactinomycin
|
Prostate carcinoma (Cell Line: PC-3)
|
[7] |
|
Ruxolitinib + DFN-15
|
DCCMHKS
|
DFN-15
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + Lapatinib
|
DC220Q6
|
Lapatinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[7] |
|
Ruxolitinib + Lapatinib
|
DCUW3PV
|
Lapatinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[7] |
|
Ruxolitinib + PMID28460551-Compound-2
|
DCHEN2Y
|
PMID28460551-Compound-2
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[7] |
|
Ruxolitinib + PMID28460551-Compound-2
|
DC6K0LE
|
PMID28460551-Compound-2
|
Melanoma (Cell Line: MALME-3M)
|
[7] |
|
Ruxolitinib + PMID28460551-Compound-2
|
DCYA4EE
|
PMID28460551-Compound-2
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[7] |
|
Ruxolitinib + Crizotinib
|
DCYBIBH
|
Crizotinib
|
Melanoma (Cell Line: UACC-257)
|
[7] |
|
Ruxolitinib + Cyclophosphamide
|
DCW865W
|
Cyclophosphamide
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[7] |
|
Ruxolitinib + Cyclophosphamide
|
DCV0BA7
|
Cyclophosphamide
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[7] |
|
Ruxolitinib + Vismodegib
|
DCXN6ZR
|
Vismodegib
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + Isoniazid
|
DCKWN3Z
|
Isoniazid
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + Isoniazid
|
DC6IIPI
|
Isoniazid
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[7] |
|
Ruxolitinib + Isoniazid
|
DCTM368
|
Isoniazid
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + Isoniazid
|
DC17XCP
|
Isoniazid
|
Melanoma (Cell Line: UACC-257)
|
[7] |
|
Ruxolitinib + Isoniazid
|
DC0HFWB
|
Isoniazid
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[7] |
|
Ruxolitinib + Isoniazid
|
DCLZ1FX
|
Isoniazid
|
Prostate carcinoma (Cell Line: PC-3)
|
[7] |
|
Ruxolitinib + Vemurafenib
|
DCZ3UEG
|
Vemurafenib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[7] |
|
Ruxolitinib + Vemurafenib
|
DCYFTCS
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + Vemurafenib
|
DCXGXQV
|
Vemurafenib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[7] |
|
Ruxolitinib + Lenalidomide
|
DCL00Y8
|
Lenalidomide
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Ruxolitinib + Lenalidomide
|
DCW24XA
|
Lenalidomide
|
Melanoma (Cell Line: MALME-3M)
|
[7] |
|
Ruxolitinib + Plicamycin
|
DCROKN8
|
Plicamycin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[7] |
|
Ruxolitinib + Plicamycin
|
DC47ZNK
|
Plicamycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[7] |
|
Ruxolitinib + Plicamycin
|
DCI2M9Q
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[7] |
|
Ruxolitinib + Plicamycin
|
DC0848B
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[7] |
|
Ruxolitinib + Plicamycin
|
DCL0QDL
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[7] |
|
Ruxolitinib + Plicamycin
|
DCYYZBV
|
Plicamycin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Ruxolitinib + Plicamycin
|
DCD1MDI
|
Plicamycin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[7] |
|
Ruxolitinib + Plicamycin
|
DC9YSLR
|
Plicamycin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[7] |
|
Ruxolitinib + Plicamycin
|
DCULFUI
|
Plicamycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[7] |
|
Ruxolitinib + Plicamycin
|
DC0QRAK
|
Plicamycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + Plicamycin
|
DCS3AML
|
Plicamycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[7] |
|
Ruxolitinib + Plicamycin
|
DCFY4S1
|
Plicamycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[7] |
|
Ruxolitinib + Plicamycin
|
DCK0CZ0
|
Plicamycin
|
Melanoma (Cell Line: UACC-257)
|
[7] |
|
Ruxolitinib + Plicamycin
|
DCB9JW5
|
Plicamycin
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + Plicamycin
|
DC2XXRV
|
Plicamycin
|
Melanoma (Cell Line: MALME-3M)
|
[7] |
|
Ruxolitinib + Plicamycin
|
DCZSVC1
|
Plicamycin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[7] |
|
Ruxolitinib + Plicamycin
|
DC700ZP
|
Plicamycin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[7] |
|
Ruxolitinib + Plicamycin
|
DCA079H
|
Plicamycin
|
Prostate carcinoma (Cell Line: PC-3)
|
[7] |
|
Ruxolitinib + Nilotinib
|
DC1FRQS
|
Nilotinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[7] |
|
Ruxolitinib + Nilotinib
|
DC6R9D5
|
Nilotinib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Ruxolitinib + Nilotinib
|
DC3Z5HI
|
Nilotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + Nilotinib
|
DCQN2Z3
|
Nilotinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[7] |
|
Ruxolitinib + Nilotinib
|
DC6OL4J
|
Nilotinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[7] |
|
Ruxolitinib + Thioguanine
|
DCI2HA0
|
Thioguanine
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + Thioguanine
|
DCSWOC4
|
Thioguanine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[7] |
|
Ruxolitinib + Thioguanine
|
DCU5MEN
|
Thioguanine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[7] |
|
Ruxolitinib + Thioguanine
|
DCWCZMJ
|
Thioguanine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[7] |
|
Ruxolitinib + Triapine
|
DCTVLED
|
Triapine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[7] |
|
Ruxolitinib + Triapine
|
DCF2K43
|
Triapine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[7] |
|
Ruxolitinib + Triapine
|
DCQ19CT
|
Triapine
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + ABIRATERONE
|
DC5Q424
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + ABIRATERONE
|
DCEO8Q7
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: SW-620)
|
[7] |
|
Ruxolitinib + ABIRATERONE
|
DC5RX20
|
ABIRATERONE
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + ABIRATERONE
|
DCXX68P
|
ABIRATERONE
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[7] |
|
Ruxolitinib + 10-hydroxycamptothecin
|
DCOAA3J
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: SW-620)
|
[7] |
|
Ruxolitinib + 10-hydroxycamptothecin
|
DCO2Z54
|
10-hydroxycamptothecin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[7] |
|
Ruxolitinib + Pralatrexate
|
DCKUBMC
|
Pralatrexate
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + Pralatrexate
|
DCG85PZ
|
Pralatrexate
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[7] |
|
Ruxolitinib + Pralatrexate
|
DC7M79T
|
Pralatrexate
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[7] |
|
Ruxolitinib + Terameprocol
|
DC8ALQ1
|
Terameprocol
|
Adenocarcinoma (Cell Line: HT29)
|
[7] |
|
Ruxolitinib + Terameprocol
|
DCKMO2D
|
Terameprocol
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[7] |
|
Ruxolitinib + Terameprocol
|
DCSAVXG
|
Terameprocol
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Ruxolitinib + Terameprocol
|
DCOBX4R
|
Terameprocol
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[7] |
|
Ruxolitinib + Terameprocol
|
DCRJZDZ
|
Terameprocol
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[7] |
|
Ruxolitinib + Terameprocol
|
DCPAFLD
|
Terameprocol
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[7] |
|
Ruxolitinib + Terameprocol
|
DCRW50U
|
Terameprocol
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + Terameprocol
|
DC17LEH
|
Terameprocol
|
Melanoma (Cell Line: UACC-257)
|
[7] |
|
Ruxolitinib + Terameprocol
|
DCHJY3R
|
Terameprocol
|
Melanoma (Cell Line: MALME-3M)
|
[7] |
|
Ruxolitinib + Terameprocol
|
DCBBHLK
|
Terameprocol
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[7] |
|
Ruxolitinib + Terameprocol
|
DCBFI6S
|
Terameprocol
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[7] |
|
Ruxolitinib + Terameprocol
|
DCXFD3Z
|
Terameprocol
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[7] |
|
Ruxolitinib + Terameprocol
|
DC8I84W
|
Terameprocol
|
Prostate carcinoma (Cell Line: PC-3)
|
[7] |
|
Ruxolitinib + SCH 727965
|
DCADPC5
|
SCH 727965
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Ruxolitinib + SCH 727965
|
DCWXNBI
|
SCH 727965
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[7] |
|
Ruxolitinib + Ifosfamide
|
DC8FZV4
|
Ifosfamide
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[7] |
|
Ruxolitinib + Dexrazoxane
|
DCXNVGV
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: A549)
|
[7] |
|
Ruxolitinib + Dexrazoxane
|
DC1GWG6
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: HCT-15)
|
[7] |
|
Ruxolitinib + Docetaxel
|
DC0TT5Q
|
Docetaxel
|
Adenocarcinoma (Cell Line: NCIH23)
|
[7] |
|
Ruxolitinib + Docetaxel
|
DCYV93J
|
Docetaxel
|
Adenocarcinoma (Cell Line: SW-620)
|
[7] |
|
Ruxolitinib + Docetaxel
|
DCWGPHR
|
Docetaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[7] |
|
Ruxolitinib + Docetaxel
|
DCOT03C
|
Docetaxel
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[7] |
|
Ruxolitinib + Docetaxel
|
DCX3SEH
|
Docetaxel
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[7] |
|
Ruxolitinib + Docetaxel
|
DCKHUR2
|
Docetaxel
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[7] |
|
Ruxolitinib + Docetaxel
|
DCNUXYZ
|
Docetaxel
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[7] |
|
Ruxolitinib + Raloxifene
|
DC11GQL
|
Raloxifene
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + Raloxifene
|
DCPJTY0
|
Raloxifene
|
Adenocarcinoma (Cell Line: NCIH23)
|
[7] |
|
Ruxolitinib + Raloxifene
|
DC51BJE
|
Raloxifene
|
Adenocarcinoma (Cell Line: HCT-15)
|
[7] |
|
Ruxolitinib + Raloxifene
|
DC69E61
|
Raloxifene
|
Adenocarcinoma (Cell Line: HCT116)
|
[7] |
|
Ruxolitinib + Raloxifene
|
DCUUP3Q
|
Raloxifene
|
Adenocarcinoma (Cell Line: HT29)
|
[7] |
|
Ruxolitinib + Raloxifene
|
DCLF6EQ
|
Raloxifene
|
Amelanotic melanoma (Cell Line: M14)
|
[7] |
|
Ruxolitinib + Raloxifene
|
DCYYI57
|
Raloxifene
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Ruxolitinib + Raloxifene
|
DCQPWGD
|
Raloxifene
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[7] |
|
Ruxolitinib + Raloxifene
|
DCTGWFL
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[7] |
|
Ruxolitinib + Raloxifene
|
DCSY3J1
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + Raloxifene
|
DCSB9M1
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[7] |
|
Ruxolitinib + Raloxifene
|
DC9E9UT
|
Raloxifene
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[7] |
|
Ruxolitinib + Raloxifene
|
DCB3RQ8
|
Raloxifene
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[7] |
|
Ruxolitinib + Raloxifene
|
DCWGVPY
|
Raloxifene
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + Raloxifene
|
DCP7V3S
|
Raloxifene
|
Melanoma (Cell Line: UACC-257)
|
[7] |
|
Ruxolitinib + Raloxifene
|
DCQEJ1M
|
Raloxifene
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[7] |
|
Ruxolitinib + Raloxifene
|
DCO22EP
|
Raloxifene
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[7] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DC05FN6
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: A549)
|
[7] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DCL08H7
|
Bendamustine hydrochloride
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[7] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DCD9VLH
|
Bendamustine hydrochloride
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[7] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DC9QSHE
|
Bendamustine hydrochloride
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[7] |
|
Ruxolitinib + Bendamustine hydrochloride
|
DCTR5AW
|
Bendamustine hydrochloride
|
Prostate carcinoma (Cell Line: PC-3)
|
[7] |
|
Ruxolitinib + Trifluridine
|
DCYOGCK
|
Trifluridine
|
Adenocarcinoma (Cell Line: SW-620)
|
[7] |
|
Ruxolitinib + Sirolimus
|
DCRCWM0
|
Sirolimus
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + Sirolimus
|
DC9CBB5
|
Sirolimus
|
Adenocarcinoma (Cell Line: NCIH23)
|
[7] |
|
Ruxolitinib + Sirolimus
|
DC9H5GM
|
Sirolimus
|
Adenocarcinoma (Cell Line: A549)
|
[7] |
|
Ruxolitinib + Sirolimus
|
DC72H01
|
Sirolimus
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[7] |
|
Ruxolitinib + Sirolimus
|
DCI76Z1
|
Sirolimus
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[7] |
|
Ruxolitinib + Sirolimus
|
DC7GGFF
|
Sirolimus
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[7] |
|
Ruxolitinib + Sirolimus
|
DCLCDII
|
Sirolimus
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[7] |
|
Ruxolitinib + Letrozole
|
DCAFCJQ
|
Letrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[7] |
|
Ruxolitinib + Letrozole
|
DCOBDZZ
|
Letrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + Letrozole
|
DC5BP62
|
Letrozole
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + Letrozole
|
DC0F35M
|
Letrozole
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[7] |
|
Ruxolitinib + Mitomycin
|
DCCP8DD
|
Mitomycin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[7] |
|
Ruxolitinib + Mitomycin
|
DCKS4RL
|
Mitomycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[7] |
|
Ruxolitinib + SY-1425
|
DCNJSBO
|
SY-1425
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[7] |
|
Ruxolitinib + Uracil mustard
|
DC72N8X
|
Uracil mustard
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + Uracil mustard
|
DC6K9N1
|
Uracil mustard
|
Adenocarcinoma (Cell Line: NCIH23)
|
[7] |
|
Ruxolitinib + Uracil mustard
|
DCKGV99
|
Uracil mustard
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[7] |
|
Ruxolitinib + Uracil mustard
|
DC9WUDT
|
Uracil mustard
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[7] |
|
Ruxolitinib + Uracil mustard
|
DCTQACX
|
Uracil mustard
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[7] |
|
Ruxolitinib + Arfolitixorin
|
DCMA4JH
|
Arfolitixorin
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + Arfolitixorin
|
DCLDE8M
|
Arfolitixorin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[7] |
|
Ruxolitinib + BIO-300
|
DCS0974
|
BIO-300
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + BIO-300
|
DCCHRGE
|
BIO-300
|
Adenocarcinoma (Cell Line: SW-620)
|
[7] |
|
Ruxolitinib + BIO-300
|
DC3IRXG
|
BIO-300
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[7] |
|
Ruxolitinib + BIO-300
|
DC6ORWL
|
BIO-300
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[7] |
|
Ruxolitinib + Altretamine
|
DCZ4FBF
|
Altretamine
|
Adenocarcinoma (Cell Line: HCT116)
|
[7] |
|
Ruxolitinib + Altretamine
|
DC9WLA6
|
Altretamine
|
Adenocarcinoma (Cell Line: HT29)
|
[7] |
|
Ruxolitinib + Altretamine
|
DCE26VT
|
Altretamine
|
Adenocarcinoma (Cell Line: SW-620)
|
[7] |
|
Ruxolitinib + Altretamine
|
DCRKJ26
|
Altretamine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Ruxolitinib + Altretamine
|
DC20J8R
|
Altretamine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + Altretamine
|
DCAOAOK
|
Altretamine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[7] |
|
Ruxolitinib + Altretamine
|
DCTO64E
|
Altretamine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[7] |
|
Ruxolitinib + Altretamine
|
DCFROKN
|
Altretamine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[7] |
|
Ruxolitinib + Altretamine
|
DCRTI4G
|
Altretamine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[7] |
|
Ruxolitinib + Altretamine
|
DCU2QMO
|
Altretamine
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + TEM
|
DCD2E8L
|
TEM
|
Adenocarcinoma (Cell Line: NCIH23)
|
[7] |
|
Ruxolitinib + TEM
|
DCTQU0V
|
TEM
|
Adenocarcinoma (Cell Line: HCT-15)
|
[7] |
|
Ruxolitinib + TEM
|
DCKS7CT
|
TEM
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[7] |
|
Ruxolitinib + TEM
|
DCSCDMH
|
TEM
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + TEM
|
DC79ZDF
|
TEM
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[7] |
|
Ruxolitinib + TEM
|
DCIVVC9
|
TEM
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + TEM
|
DCU316K
|
TEM
|
Melanoma (Cell Line: UACC-257)
|
[7] |
|
Ruxolitinib + JNK-IN-8
|
DC3FFPC
|
JNK-IN-8
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + JNK-IN-8
|
DCFJZEF
|
JNK-IN-8
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[7] |
|
Ruxolitinib + JNK-IN-8
|
DCPVPTA
|
JNK-IN-8
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[7] |
|
Ruxolitinib + JNK-IN-8
|
DC79PLS
|
JNK-IN-8
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[7] |
|
Ruxolitinib + Indazole derivative 5
|
DCOIAQY
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + Indazole derivative 5
|
DC6PNCY
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: NCIH23)
|
[7] |
|
Ruxolitinib + Indazole derivative 5
|
DCEA6CM
|
Indazole derivative 5
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[7] |
|
Ruxolitinib + Indazole derivative 5
|
DCULUAE
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + Indazole derivative 5
|
DCBPFDP
|
Indazole derivative 5
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[7] |
|
Ruxolitinib + Indazole derivative 5
|
DCFCH7V
|
Indazole derivative 5
|
Melanoma (Cell Line: MALME-3M)
|
[7] |
|
Ruxolitinib + Indazole derivative 5
|
DCD7KCW
|
Indazole derivative 5
|
Melanoma (Cell Line: UACC-257)
|
[7] |
|
Ruxolitinib + Indazole derivative 5
|
DCX8ZCI
|
Indazole derivative 5
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + Indazole derivative 5
|
DC39G4B
|
Indazole derivative 5
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[7] |
|
Ruxolitinib + Indazole derivative 5
|
DCR3WS5
|
Indazole derivative 5
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[7] |
|
Ruxolitinib + Indazole derivative 5
|
DCNFVQ5
|
Indazole derivative 5
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[7] |
|
Ruxolitinib + Indazole derivative 5
|
DCGFSUI
|
Indazole derivative 5
|
Prostate carcinoma (Cell Line: PC-3)
|
[7] |
|
Ruxolitinib + Imatinib
|
DCXQL46
|
Imatinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[7] |
|
Ruxolitinib + Imatinib
|
DCJNO1V
|
Imatinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[7] |
|
Ruxolitinib + Bleomycin
|
DCF5AJ0
|
Bleomycin
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + Bleomycin
|
DCP0ZND
|
Bleomycin
|
Adenocarcinoma (Cell Line: A549)
|
[7] |
|
Ruxolitinib + Bleomycin
|
DCK63BX
|
Bleomycin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[7] |
|
Ruxolitinib + Bleomycin
|
DCF8CKM
|
Bleomycin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[7] |
|
Ruxolitinib + Bleomycin
|
DC8KX8J
|
Bleomycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[7] |
|
Ruxolitinib + Bortezomib
|
DCWRTNH
|
Bortezomib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[7] |
|
Ruxolitinib + Bortezomib
|
DCPCSS9
|
Bortezomib
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + Bortezomib
|
DCKN1TP
|
Bortezomib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[7] |
|
Ruxolitinib + Anastrozole
|
DCRL59M
|
Anastrozole
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[7] |
|
Ruxolitinib + Anastrozole
|
DC7Z4DT
|
Anastrozole
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[7] |
|
Ruxolitinib + Dacarbazine
|
DCDNLJF
|
Dacarbazine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[7] |
|
Ruxolitinib + Dacarbazine
|
DCW6KG3
|
Dacarbazine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Ruxolitinib + Dacarbazine
|
DCE8NXU
|
Dacarbazine
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[7] |
|
Ruxolitinib + Dacarbazine
|
DCB6CFH
|
Dacarbazine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + Dacarbazine
|
DCZ9YTF
|
Dacarbazine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[7] |
|
Ruxolitinib + Dacarbazine
|
DCUNPKN
|
Dacarbazine
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + Dacarbazine
|
DCXFF18
|
Dacarbazine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[7] |
|
Ruxolitinib + Valrubicin
|
DCT4SYF
|
Valrubicin
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + Valrubicin
|
DCUN36F
|
Valrubicin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Ruxolitinib + Valrubicin
|
DCYAY5M
|
Valrubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + Valrubicin
|
DC67DSC
|
Valrubicin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[7] |
|
Ruxolitinib + Valrubicin
|
DCBEKKT
|
Valrubicin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[7] |
|
Ruxolitinib + Valrubicin
|
DCDT7J1
|
Valrubicin
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + Valrubicin
|
DCLY8Q7
|
Valrubicin
|
Melanoma (Cell Line: MALME-3M)
|
[7] |
|
Ruxolitinib + Valrubicin
|
DCHDEZU
|
Valrubicin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[7] |
|
Ruxolitinib + Topotecan
|
DCVCB1S
|
Topotecan
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[7] |
|
Ruxolitinib + Topotecan
|
DCF52RI
|
Topotecan
|
Melanoma (Cell Line: MALME-3M)
|
[7] |
|
Ruxolitinib + Topotecan
|
DCXL6TB
|
Topotecan
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[7] |
|
Ruxolitinib + Topotecan
|
DCI2W3U
|
Topotecan
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[7] |
|
Ruxolitinib + Topotecan
|
DCQSO68
|
Topotecan
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[7] |
|
Ruxolitinib + Cabazitaxel
|
DCVB3IC
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + Cabazitaxel
|
DC1X4VJ
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: A549)
|
[7] |
|
Ruxolitinib + Cabazitaxel
|
DCYCGZW
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: NCIH23)
|
[7] |
|
Ruxolitinib + Cabazitaxel
|
DCN2JM4
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: SW-620)
|
[7] |
|
Ruxolitinib + Cabazitaxel
|
DC086JL
|
Cabazitaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[7] |
|
Ruxolitinib + Cabazitaxel
|
DC1TK6P
|
Cabazitaxel
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[7] |
|
Ruxolitinib + Cabazitaxel
|
DCRQO7V
|
Cabazitaxel
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[7] |
|
Ruxolitinib + Epirubicin
|
DC5WXRQ
|
Epirubicin
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + Epirubicin
|
DCY711Y
|
Epirubicin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[7] |
|
Ruxolitinib + Epirubicin
|
DCQB6TH
|
Epirubicin
|
Adenocarcinoma (Cell Line: HCT116)
|
[7] |
|
Ruxolitinib + Epirubicin
|
DCFK8Q3
|
Epirubicin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Ruxolitinib + Epirubicin
|
DCM00OP
|
Epirubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[7] |
|
Ruxolitinib + Epirubicin
|
DCMB7NV
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[7] |
|
Ruxolitinib + Epirubicin
|
DC80N1V
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + Epirubicin
|
DC4OMHK
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[7] |
|
Ruxolitinib + Epirubicin
|
DC84JJZ
|
Epirubicin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[7] |
|
Ruxolitinib + Epirubicin
|
DC7YJU6
|
Epirubicin
|
Melanoma (Cell Line: UACC-257)
|
[7] |
|
Ruxolitinib + Epirubicin
|
DCCYMY0
|
Epirubicin
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + Cisplatin
|
DCXFBIT
|
Cisplatin
|
Adenocarcinoma (Cell Line: HT29)
|
[7] |
|
Ruxolitinib + Cisplatin
|
DCXZOX1
|
Cisplatin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[7] |
|
Ruxolitinib + Cisplatin
|
DCOOYLR
|
Cisplatin
|
Melanoma (Cell Line: MALME-3M)
|
[7] |
|
Ruxolitinib + Vandetanib
|
DCAHA17
|
Vandetanib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Ruxolitinib + Vandetanib
|
DCU8JDM
|
Vandetanib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[7] |
|
Ruxolitinib + Chlorambucil
|
DCBVM8V
|
Chlorambucil
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[7] |
|
Ruxolitinib + ER819762
|
DCNL94R
|
ER819762
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[7] |
|
Ruxolitinib + ER819762
|
DCDZH5S
|
ER819762
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + ER819762
|
DCIWKRJ
|
ER819762
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + Romidepsin
|
DC24GQM
|
Romidepsin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[7] |
|
Ruxolitinib + Romidepsin
|
DCPBQ5W
|
Romidepsin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[7] |
|
Ruxolitinib + Azacitidine
|
DCEIUIT
|
Azacitidine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Ruxolitinib + Pomalidomide
|
DCKXHS6
|
Pomalidomide
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + Pomalidomide
|
DCWVBYU
|
Pomalidomide
|
Adenocarcinoma (Cell Line: HCT-15)
|
[7] |
|
Ruxolitinib + Pomalidomide
|
DC40ZM2
|
Pomalidomide
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Ruxolitinib + Pomalidomide
|
DCF2KBJ
|
Pomalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[7] |
|
Ruxolitinib + Pomalidomide
|
DC7WGFT
|
Pomalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[7] |
|
Ruxolitinib + Pomalidomide
|
DCPQNQ7
|
Pomalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + Pomalidomide
|
DCYUCJW
|
Pomalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[7] |
|
Ruxolitinib + Pomalidomide
|
DC20Q3N
|
Pomalidomide
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[7] |
|
Ruxolitinib + Pomalidomide
|
DC51DGW
|
Pomalidomide
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[7] |
|
Ruxolitinib + Pomalidomide
|
DC48IRL
|
Pomalidomide
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[7] |
|
Ruxolitinib + Pomalidomide
|
DCKNCPZ
|
Pomalidomide
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + Pomalidomide
|
DCC3E43
|
Pomalidomide
|
Melanoma (Cell Line: MALME-3M)
|
[7] |
|
Ruxolitinib + Pomalidomide
|
DCOWHQB
|
Pomalidomide
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[7] |
|
Ruxolitinib + Pomalidomide
|
DC37MAG
|
Pomalidomide
|
Prostate carcinoma (Cell Line: PC-3)
|
[7] |
|
Ruxolitinib + Mercaptopurine
|
DC5N5QF
|
Mercaptopurine
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[7] |
|
Ruxolitinib + Mepacrine
|
DCAD71Q
|
Mepacrine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + Taxol
|
DCNAFFC
|
Taxol
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + Taxol
|
DCB8KTB
|
Taxol
|
Adenocarcinoma (Cell Line: A549)
|
[7] |
|
Ruxolitinib + Taxol
|
DC0I0NI
|
Taxol
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[7] |
|
Ruxolitinib + Taxol
|
DCPDN0J
|
Taxol
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[7] |
|
Ruxolitinib + Taxol
|
DCTW0K0
|
Taxol
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[7] |
|
Ruxolitinib + Taxol
|
DC5AWHY
|
Taxol
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[7] |
|
Ruxolitinib + Fludarabine
|
DCJ554J
|
Fludarabine
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + PMID28870136-Compound-43
|
DCEIU2G
|
PMID28870136-Compound-43
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Ruxolitinib + PMID28870136-Compound-43
|
DCDIR6C
|
PMID28870136-Compound-43
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[7] |
|
Ruxolitinib + PMID28870136-Compound-43
|
DCATM99
|
PMID28870136-Compound-43
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + PMID28870136-Compound-43
|
DCQUQR8
|
PMID28870136-Compound-43
|
Melanoma (Cell Line: MALME-3M)
|
[7] |
|
Ruxolitinib + PMID28870136-Compound-43
|
DCT31GG
|
PMID28870136-Compound-43
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + PMID28870136-Compound-43
|
DCM0Q9M
|
PMID28870136-Compound-43
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[7] |
|
Ruxolitinib + FORMESTANE
|
DCYGK2E
|
FORMESTANE
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Ruxolitinib + FORMESTANE
|
DC21T4O
|
FORMESTANE
|
Melanoma (Cell Line: MALME-3M)
|
[7] |
|
Ruxolitinib + FORMESTANE
|
DCTE6K9
|
FORMESTANE
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Ruxolitinib + FORMESTANE
|
DC4WBOO
|
FORMESTANE
|
Melanoma (Cell Line: UACC-257)
|
[7] |
|
Ruxolitinib + FORMESTANE
|
DCVWSPK
|
FORMESTANE
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[7] |
|
Ruxolitinib + Aminolevulinic Acid Hydrochloride
|
DCIQSTY
|
Aminolevulinic Acid Hydrochloride
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[7] |
|
Ruxolitinib + Estramustine
|
DC7Q9BN
|
Estramustine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Ruxolitinib + Busulfan
|
DCM2PIN
|
Busulfan
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[7] |
|
Ruxolitinib + Dasatinib
|
DCOAK3V
|
Dasatinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[7] |
|
Ruxolitinib + Dasatinib
|
DCNWWXK
|
Dasatinib
|
Adenocarcinoma (Cell Line: A549)
|
[7] |
|
Ruxolitinib + Dasatinib
|
DCAJIC7
|
Dasatinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[7] |
|
Ruxolitinib + Dasatinib
|
DCPE7WK
|
Dasatinib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[7] |
|
Ruxolitinib + Dasatinib
|
DCMLXNI
|
Dasatinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[7] |
|
Ruxolitinib + Dasatinib
|
DCT21D2
|
Dasatinib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[7] |
|
Ruxolitinib + Dasatinib
|
DC3NWWE
|
Dasatinib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[7] |
|
Ruxolitinib + Dasatinib
|
DC35A7W
|
Dasatinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[7] |
|
Ruxolitinib + Dasatinib
|
DCHDQL0
|
Dasatinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[7] |
|
Ruxolitinib + Dasatinib
|
DCW2O98
|
Dasatinib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[7] |
|
Ruxolitinib + Dasatinib
|
DCTLSSZ
|
Dasatinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[7] |
|
Ruxolitinib + Dasatinib
|
DC85G4X
|
Dasatinib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[7] |
|
Ruxolitinib + Dasatinib
|
DC1FD43
|
Dasatinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[7] |
|
SAG + Ruxolitinib
|
DCRFPN0
|
SAG
|
Hodgkin lymphoma (Cell Line: HDLM-2)
|
[7] |
|
SB-505124 + Ruxolitinib
|
DCKVJGF
|
SB-505124
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
SCH-900776 + Ruxolitinib
|
DCD5WAE
|
SCH-900776
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Secnidazole + Ruxolitinib
|
DCQ7GN6
|
Secnidazole
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Sirolimus + Ruxolitinib
|
DCFWIW4
|
Sirolimus
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Sirolimus + Ruxolitinib
|
DCXE2HE
|
Sirolimus
|
Hodgkin lymphoma (Cell Line: HDLM-2)
|
[7] |
|
SNS-032 + Ruxolitinib
|
DCMA3HD
|
SNS-032
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
SNS-314 + Ruxolitinib
|
DCT884D
|
SNS-314
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
SNX-5422 + Ruxolitinib
|
DCA9SRU
|
SNX-5422
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
SNX-5422 + Ruxolitinib
|
DCXGNB6
|
SNX-5422
|
Hodgkin lymphoma (Cell Line: HDLM-2)
|
[7] |
|
SNX-5422 + Ruxolitinib
|
DCBMO56
|
SNX-5422
|
Hodgkin lymphoma (Cell Line: L-428)
|
[7] |
|
SR9011 + Ruxolitinib
|
DC7MP4K
|
SR9011
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
SSR-125047 + Ruxolitinib
|
DCA5U97
|
SSR-125047
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Stavudine + Ruxolitinib
|
DCEHBD1
|
Stavudine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Sulfameter + Ruxolitinib
|
DC7HQ4J
|
Sulfameter
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Sulfanilamide + Ruxolitinib
|
DC5EZ5F
|
Sulfanilamide
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Sulindac + Ruxolitinib
|
DC4YIKK
|
Sulindac
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Sumatriptan + Ruxolitinib
|
DCE3ANI
|
Sumatriptan
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Tacedinaline + Ruxolitinib
|
DCZFDS2
|
Tacedinaline
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
TAK-715 + Ruxolitinib
|
DCEA3XA
|
TAK-715
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
TAK165 + Ruxolitinib
|
DCTEM0R
|
TAK165
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Tanespimycin + Ruxolitinib
|
DC3A9WO
|
Tanespimycin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
TCN-P + Ruxolitinib
|
DC9GU33
|
TCN-P
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Teicoplanin + Ruxolitinib
|
DC4GQ1G
|
Teicoplanin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Testosterone + Ruxolitinib
|
DC2CU5W
|
Testosterone
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Tetrahydrouridine + Ruxolitinib
|
DCKK6ZP
|
Tetrahydrouridine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
TG100-115 + Ruxolitinib
|
DCDOZ60
|
TG100-115
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
TG100801 + Ruxolitinib
|
DCU7G4J
|
TG100801
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
THAPSIGARGIN + Ruxolitinib
|
DCQ8JL5
|
THAPSIGARGIN
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Tigecycline + Ruxolitinib
|
DCHTAGC
|
Tigecycline
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Tolnaftate + Ruxolitinib
|
DCNDMPI
|
Tolnaftate
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Tolvaptan + Ruxolitinib
|
DC2IB5K
|
Tolvaptan
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Topetecan + Ruxolitinib
|
DCZYPH3
|
Topetecan
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Torin 1 + Ruxolitinib
|
DCOL0ZB
|
Torin 1
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Torin2 + Ruxolitinib
|
DCUV394
|
Torin2
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Torin2 + Ruxolitinib
|
DCP2MMX
|
Torin2
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
TPCA-1 + Ruxolitinib
|
DCH0PS3
|
TPCA-1
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Trazodone + Ruxolitinib
|
DCBNAQU
|
Trazodone
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Tretinoin + Ruxolitinib
|
DCBL0P4
|
Tretinoin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Trichostatin A + Ruxolitinib
|
DCUO4RH
|
Trichostatin A
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Triciribine + Ruxolitinib
|
DCZFYT3
|
Triciribine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Trioxsalen + Ruxolitinib
|
DC6SV0N
|
Trioxsalen
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Tropisetron + Ruxolitinib
|
DCZLAPF
|
Tropisetron
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
TW-37 + Ruxolitinib
|
DCNK6YX
|
TW-37
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
UK-383367 + Ruxolitinib
|
DCZM3BW
|
UK-383367
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
URSOLIC ACID + Ruxolitinib
|
DC1W4ZZ
|
URSOLIC ACID
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
V81444 + Ruxolitinib
|
DCIFECF
|
V81444
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Valaciclovir + Ruxolitinib
|
DC78DKN
|
Valaciclovir
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Valspodar + Ruxolitinib
|
DCSM9BC
|
Valspodar
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Vandetanib + Ruxolitinib
|
DCDELCM
|
Vandetanib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[9] |
|
Vandetanib + Ruxolitinib
|
DCZR86Y
|
Vandetanib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Vandetanib + Ruxolitinib
|
DCHMI2M
|
Vandetanib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[7] |
|
Vandetanib + Ruxolitinib
|
DCX28F1
|
Vandetanib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[7] |
|
Vandetanib + Ruxolitinib
|
DCJD7CA
|
Vandetanib
|
Amelanotic melanoma (Cell Line: M14)
|
[7] |
|
Vandetanib + Ruxolitinib
|
DC3GZ6Q
|
Vandetanib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[7] |
|
Vandetanib + Ruxolitinib
|
DCOFCWS
|
Vandetanib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[7] |
|
Vandetanib + Ruxolitinib
|
DCJZC0C
|
Vandetanib
|
Glioma (Cell Line: SF-268)
|
[7] |
|
Vandetanib + Ruxolitinib
|
DCG7YNV
|
Vandetanib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[7] |
|
Vemurafenib + Ruxolitinib
|
DC0TMPZ
|
Vemurafenib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[7] |
|
Vemurafenib + Ruxolitinib
|
DCJBFTN
|
Vemurafenib
|
Adenocarcinoma (Cell Line: HCT116)
|
[7] |
|
Vemurafenib + Ruxolitinib
|
DCSDO7V
|
Vemurafenib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[7] |
|
Vemurafenib + Ruxolitinib
|
DCEH8YY
|
Vemurafenib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[7] |
|
Vemurafenib + Ruxolitinib
|
DCR87HO
|
Vemurafenib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[7] |
|
Vemurafenib + Ruxolitinib
|
DCTOM4D
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[7] |
|
Vemurafenib + Ruxolitinib
|
DC0K09C
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[7] |
|
Vemurafenib + Ruxolitinib
|
DCJAS3S
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[7] |
|
Vemurafenib + Ruxolitinib
|
DCVNXSH
|
Vemurafenib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[7] |
|
Vemurafenib + Ruxolitinib
|
DCEASGV
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[7] |
|
Vemurafenib + Ruxolitinib
|
DCJG9MQ
|
Vemurafenib
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Venglustat + Ruxolitinib
|
DCVIEW8
|
Venglustat
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Vinblastine + Ruxolitinib
|
DCLW1T3
|
Vinblastine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Vincristine + Ruxolitinib
|
DCHRZ67
|
Vincristine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Vincristine + Ruxolitinib
|
DCI91NL
|
Vincristine
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Vinorelbine + Ruxolitinib
|
DC0FTTL
|
Vinorelbine
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Vismodegib + Ruxolitinib
|
DCP6Z24
|
Vismodegib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[9] |
|
Vismodegib + Ruxolitinib
|
DCWXU8Z
|
Vismodegib
|
Carcinoma (Cell Line: MCF7)
|
[9] |
|
Vismodegib + Ruxolitinib
|
DCADQH3
|
Vismodegib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[9] |
|
Vismodegib + Ruxolitinib
|
DC0445L
|
Vismodegib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[7] |
|
Vismodegib + Ruxolitinib
|
DC2HYA5
|
Vismodegib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[7] |
|
Vismodegib + Ruxolitinib
|
DCE8GR2
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[7] |
|
Vismodegib + Ruxolitinib
|
DCAUL4C
|
Vismodegib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[7] |
|
Vismodegib + Ruxolitinib
|
DC8AOQK
|
Vismodegib
|
Glioma (Cell Line: SF-268)
|
[7] |
|
Vismodegib + Ruxolitinib
|
DC0UVI9
|
Vismodegib
|
Hodgkin lymphoma (Cell Line: L-428)
|
[7] |
|
Vismodegib + Ruxolitinib
|
DCCMW8F
|
Vismodegib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Vismodegib + Ruxolitinib
|
DCZ9I3O
|
Vismodegib
|
Melanoma (Cell Line: SK-MEL-2)
|
[7] |
|
Vismodegib + Ruxolitinib
|
DCB2NYW
|
Vismodegib
|
Melanoma (Cell Line: MALME-3M)
|
[7] |
|
Vismodegib + Ruxolitinib
|
DCM2XE5
|
Vismodegib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[7] |
|
Volasertib + Ruxolitinib
|
DC1HW1J
|
Volasertib
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Volasertib + Ruxolitinib
|
DC3YE2D
|
Volasertib
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Volasertib + Ruxolitinib
|
DC06IQI
|
Volasertib
|
Hodgkin lymphoma (Cell Line: L-428)
|
[7] |
|
Vorinostat + Ruxolitinib
|
DCR76A1
|
Vorinostat
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
VR-776 + Ruxolitinib
|
DCQ3XA7
|
VR-776
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
VX-680 + Ruxolitinib
|
DCEDWSZ
|
VX-680
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
VX-944 + Ruxolitinib
|
DCGUGMV
|
VX-944
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
WAY-100635 + Ruxolitinib
|
DCXDNJK
|
WAY-100635
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Withaferin A + Ruxolitinib
|
DCJ0KR2
|
Withaferin A
|
T-cell leukemia/lymphoma (Cell Line: ED-40515)
|
[8] |
|
Withaferin A + Ruxolitinib
|
DC9TFIC
|
Withaferin A
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
Wortmannin + Ruxolitinib
|
DCL5LE5
|
Wortmannin
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
Zoledronate + Ruxolitinib
|
DC5OO7T
|
Zoledronate
|
Hodgkin lymphoma (Cell Line: HDLM-2)
|
[7] |
|
Zoledronate + Ruxolitinib
|
DC6J1BT
|
Zoledronate
|
Hodgkin lymphoma (Cell Line: L-428)
|
[7] |
|
Zoledronate + Ruxolitinib
|
DCKE48P
|
Zoledronate
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
|
ZSTK474 + Ruxolitinib
|
DC7W956
|
ZSTK474
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[8] |
|
[3H]LY341495 + Ruxolitinib
|
DC71CH9
|
[3H]LY341495
|
Hodgkin lymphoma (Cell Line: L-1236)
|
[7] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
